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PARTICULATE MATTER EXPOSURE AND COMMUNITY-ACQUIRED 
PNEUMONIA MORTALITY AMONG HOSPITALIZED ADULTS WITH 
PNEUMOCOCCAL PNEUMONIA: INCIDENCE STUDY (HAPPI) PARTICIPANTS 
Jack Anthony Pfeiffer 
March 25, 2021 
 The role of air pollution as an agent of elevated morbidity and mortality has come 
under increasingly intense scrutiny in recent years. As the body of literature grows, so too 
does our understanding of how extensive the harm of such pollutants can be. Particulate 
matter (PM) particularly harmful due to its small size, ability to travel great distance while 
airborne, and capacity to infiltrate numerous bodily systems, often to the detriment of those 
exposed. Besides being associated with increased mortality risk in more heavily exposed 
populations, PM exposure has also been associated with complications in the respiratory, 
cardiovascular, and nervous systems. Additionally, exposures to PM are often unequally 
distributed among populations, with the greatest burden placed upon already marginalized 
groups. The purpose of this dissertation study was to examine the impact of PM exposure 
at the time of hospitalization on pneumonia-related mortality risk among individuals 
hospitalized due to community-acquired pneumonia (CAP). 
 The study sample for this dissertation work came from the Hospitalized Adults with 
Pneumococcal Pneumonia: Incidence (HAPPI) study conducted in Jefferson County, KY, 
USA from 2014 to 2016, containing adult residents of the county who were hospitalized 
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due to CAP during that timeframe. PM10 and PM2.5 concentration data were derived from 
online sources published by the US Environmental Protection Agency (EPA) based on a 
limited number of air monitoring stations located within Jefferson County. A spatial 
interpolation method called spatial averaging was used to determine specific levels of PM 
exposure ascribed to each participant at the time of their hospitalization. Mortality within 
thirty days of hospitalization was the primary outcome examined as it is likely to reflect 
CAP-specific mortality. The relationships between PM exposures and mortality were 
examined using a variety of methods, including logistic and Cox proportional hazards 
regression and we additionally conducted effect modification analyses. Feasibility of 
alternative spatial interpolation methods was also examined. 
 Age and race, as well as a number of hospitalization and medical history-oriented 
covariates, were found to be significantly associated with mortality in preliminary 
regression analysis. According to the preferred model containing all noted confounders and 
strong predictors, the primary PM exposures of interest were not found to be significantly 
associated with mortality; however, effect modification analysis did yield significant 
results. Black participants exposed to higher levels of PM10 had a greater odds of thirty-
day mortality, based on both continuous PM10 (AOR = 1.19 per five-unit increase, 95% CI 
= 1.04-1.37) and PM10 quartiles (greatest versus lowest quartile; AOR = 2.70, 95% CI = 
1.31-5.55). Female participants in the greatest PM10 exposure quartile had higher odds of 
death within thirty days versus those in the lowest quartile (AOR = 1.46, 95% CI = 1.01-
2.14). The same elevated associations were not observed among white or male participants. 
Additionally, the more advanced spatial interpolation method kriging was not found to be 
feasible due to sparsity of monitor data at a given time point. 
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 The results of the study indicate that certain segments of the population may be 
disproportionately impacted by PM10 exposure. Additionally, the results provide insight 
into the risks and benefits associated with specific hospitalization / medical history-
oriented covariates. Given the simplistic nature of spatial averaging and the inability to 
properly conduct kriging with the data that was available, future research on this subject 
would benefit greatly from alternative, more extensive sources of PM data within cities. 
For now, it appears that PM10 exposure is associated with elevated thirty-day mortality 
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 Particulate matter (PM) is a type of air pollutant produced through natural and 
anthropogenic means. Due to its small size, PM travels easily through the air, with exposure 
most commonly occurring through inhalation. PM has been linked to numerous detrimental 
health outcomes, including elevated all-cause and cause-specific mortality risk. Studies 
have shown that exposure to PM is associated with increased pneumonia risk, but limited 
studies exist on the impact of PM exposure on pneumonia mortality. Pneumonia is 
responsible for approximately 50,000 deaths in the United States (US) each year. Given 
the ubiquitous nature of PM and its known association with respiratory complications, 
exacerbation of pneumonia symptoms by PM exposure may pose a serious threat to public 
health, particularly for the populations that are most vulnerable, such as those over the age 
of sixty-five years.  
Jefferson County, Kentucky has a dense automotive-reliant population, has 
occurrences of violations of ambient PM concentration limits set by the US Environmental 
Protection Agency (EPA), and contains many point sources of PM within its boundaries, 
suggesting elevated exposure may be a concern for area residents. In this dissertation, the 
relationship between PM10 and PM2.5 exposure and mortality in adults hospitalized for 
community acquired pneumonia (CAP) in Jefferson County from the Hospitalized Adults 
with Pneumococcal Pneumonia: Incidence Study (HAPPI) cohort acquired from 
University of Louisville (UofL) School of Medicine Division of Infectious Diseases was 
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evaluated. Various spatial interpolation methods exist for estimating PM concentration; 
two methods, one simple and one comparatively complex, were employed to allow for the 
comparison of PM estimation methods. This study examined the relationship between PM 
exposure and pneumonia mortality in the HAPPI cohort of predominately elderly 
population within Jefferson County, KY. 
 To achieve this goal, the following specific aims were evaluated: 
1. Analysis of the relationship between PM10 and PM2.5 exposure and 30-day mortality in 
HAPPI participants, with PM concentration values being interpolated using spatial 
averaging, and said values examined using the following criteria: dichotomization 
based on National Ambient Air Quality Standards (NAAQS) cutoffs, analysis as a 
continuous exposure variable, and creation of quartiles to assess non-linear 
associations with mortality.  
2. Examination of kriging validity as a means of interpolation given sparsity of data. 











 Pneumonia can be generally defined as inflammation of the lungs, most commonly 
caused by an infectious agent, and often characterized by the presence of fluid or pus within 
the affected areas. The condition can be categorized based on a variety of parameters, 
including the geographic location where the patient acquired the condition, the type of 
infectious agent causing the condition, and the affected area of the lung. Pneumonia 
symptoms may vary depending on the type of pneumonia present and the individual’s 
profile can include cough, fever, chills, pleuritic chest pain, shortness of breath, sputum 
production, tachypnea, and tachycardia. Despite being treatable in many cases, pneumonia 
remains a leading infectious cause of death among the very young and old and is 
responsible for approximately 50,000 deaths per year in the United States of America 
(USA) alone (1). An estimated three million died from lower respiratory tract infections, 
including pneumonia, globally in 2016 (2).  Community-acquired pneumonia is a type of 
lower respiratory tract infection. Lower respiratory tract infections are a category of 
diseases estimated to be the greatest communicable cause of death and fourth leading cause 
of death worldwide (2).   
 In this introduction, a general background for pneumonia classifications is 
provided, along with epidemiologic information about community-acquired pneumonia 
among adults eighteen years of age and older, and whether air pollutants can affect 
mortality and hospitalization rates in this adult patient population. 
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Pneumonia Classification and Etiology 
 The type of pneumonia diagnosed is classified based upon several factors: where 
the disease was acquired, etiology, and the affected area of the lung. The setting in which 
the disease was acquired is of great clinical importance, as this often helps dictate the type 
of treatment that will be used. Community-acquired pneumonia and nosocomial 
pneumonia are two primary classifications of setting-specific pneumonia (3).  
Community-acquired pneumonia is pneumonia that develops outside of a hospital 
or healthcare-related setting, resulting in either outpatient or inpatient treatment depending 
on severity. Community-acquired pneumonia is the most common type observed (4). In 
addition to high rates of morbidity and mortality, this condition also results in massive cost 
burdens on the US healthcare system; a study published in 2018 estimated the yearly 
amount spent on community-acquired pneumonia hospitalizations of individuals 65 years 
and older alone exceeded one billion dollars (5), and data from 2011 suggested overall US 
pneumonia-related medical expenditures for the year to be in excess of ten billion dollars 
(6).  
The infectious agents capable of inducing community-acquired pneumonia are 
legion, encompassing a wide array of bacterial, fungal, protozoal, and viral entities. 
Bacteria and viruses are the most common causal pathogens. The onset of community-
acquired pneumonia can be attributed to such pathogenic agents as severe acute respiratory 
syndrome coronavirus 2 (COVID-19), human metapneumovirus, human parainfluenza 
virus, influenza, legionnaires disease, Mycoplasma pneumoniae, pneumococcus, 
pneumocystis, respiratory syncytial virus, and rhinovirus, among other etiologies (7). The 
most common etiological causes of community-acquired pneumonia resulting in outpatient 
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treatment are Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus 
influenzae, Chlamydophila pneumoniae, and respiratory viruses such as adenovirus, 
influenza A and B, parainfluenza, and respiratory syncytial virus (7). The most common 
etiological causes of community-acquired pneumonia resulting in non-intensive care unit 
inpatient treatment are Streptococcus pneumoniae, Mycoplasma pneumoniae, 
Chlamydophila pneumoniae, Haemophilus influenzae, Legionella species, aspiration, and 
respiratory viruses – those previously detailed (7). The most common etiological causes of 
community-acquired pneumonia resulting in intensive care unit inpatient treatment are 
Streptococcus pneumoniae, Staphylococcus aureus, Legionella species, gram-negative 
bacilli, and Haemophilus influenzae (7). In light of the recent pandemic, it is likely severe 
acute respiratory syndrome coronavirus 2 would be included in these lists as well. 
Nosocomial pneumonia includes subclassifications such as hospital-acquired 
pneumonia and ventilator-associated pneumonia. Hospital-acquired pneumonia is 
pneumonia that develops after a minimum of two days following hospital admission, 
presumably due to a hospital-related cause. Healthcare-associated pneumonia was a 
classification connected to, but different from hospital-acquired pneumonia, and 
encompassed pneumonia that could be attributed to such factors as being on dialysis 
treatment, use of immunosuppression therapies, recent hospital stays, and being a resident 
of a nursing facility. In recent years, healthcare-associated pneumonia has been removed 
as a classification. It was once believed that those exposed to the various facets of the 
healthcare system connected to the healthcare-associated pneumonia classification were 
more likely to develop pneumonia as a result of infection by multidrug-resistant organisms, 
but this was later contested (8, 9); use of healthcare-associated pneumonia as a 
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classification resulted in the improper usage of antibiotic treatments. Lastly, ventilator-
associated pneumonia is pneumonia that develops after a minimum of two days after 
endotracheal intubation.  
Epidemiology of Community-Acquired Pneumonia 
Incidence of Community-Acquired Pneumonia 
Great efforts have been made to adequately characterize community-acquired 
pneumonia incidence. In the United States, one such effort was the 2010 Etiology of 
Pneumonia in the Community (EPIC) study carried out by the Centers for Disease Control 
and Prevention (CDC) and eight affiliated hospitals and medical centers (6). The purpose 
of the study was to determine the burden of community-acquired pneumonia 
hospitalizations among children and adults. A total of 2,488 adult participants (median age 
was 57 years) hospitalized for pneumonia in any of five affiliated hospitals located in 
Chicago and Nashville were enrolled between January 2010 and June 2012. Among the 
2,320 participants with radiographic evidence of pneumonia, 498 (21.5%) required 
intensive care and 52 (2.2%) died. Among the 2,259 participants with pathogens detected 
from biological specimens and radiographic evidence of pneumonia, viruses were the 
pathogen most frequently found to be present, followed by bacteria. The most common 
pathogens found were human rhinovirus, influenza virus, and Streptococcus pneumoniae.  
The average annual community-acquired pneumonia incidence for the EPIC 
population was found to be 24.8 cases per 10,000 adults (95% CI: 23.5 – 26.1) (6). Older 
adults had higher incidence, with adults 18 to 49 years of age having an incidence of 6.7 
cases per 10,000 adults (95% CI: 6.1 – 7.3), adults 50 to 64 years of age having an incidence 
of 26.3 cases per 10,000 adults (95% CI: 24.1 – 28.7), adults 65 to 79 years of age having 
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an incidence of 63.0 cases per 10,000 (95% CI: 56.4 – 70.3), and adults 80 years of age or 
older having an incidence of 164.3 cases per 10,000 adults (95% CI: 141.9 – 189.3). The 
average annual incidence from EPIC was similar to the 26.7 cases per 10,000 adults found 
in a previous prospective study carried out in Ohio in 1991 (10), suggesting that overall 
community-acquired pneumonia incidence has not changed that greatly in the US. 
Incidence of community acquired pneumonia in the US is higher within older age groups, 
and average incidence is relatively similar to rates seen in some western countries (11-13). 
Another more recent study conducted on this topic was the Pneumonia Incidence 
Study, carried out by the University of Louisville (UofL) Pneumonia Study Group (14). 
The Group was a multidisciplinary association including UofL Infectious Disease, 
Pulmonary Medicine, and Pathology, Louisville Metro Public Health and Wellness, and 
the Kentucky Office of Vital Statistics. The study was a prospective, population-based 
study containing all hospitalized adults with CAP in Louisville, KY between June 1, 2014, 
and May 31, 2016. The purpose of the study was to determine the incidence of patients 
hospitalized with CAP. CAP incidence was calculated for both the study area and for the 
US as a whole; US incidence was calculated by multiplying the Louisville incidence by the 
total approximate US adult population of 2014. Unique (non-repeat) annual CAP incidence 
for the study area was found to be 634 cases per 100,000 adults (63.4 per 10,000 adults); 
age-adjusted annual incidence was 649 cases per 100,000 adults. CAP incidence for the 
US was estimated to be 1,555,034 adults per year; age-adjusted incidence was estimated to 
be 1,591,825 adults per year. Incidence distinctions by age were observed, annual unique 
incidence in patients 18-64 years of age being 327 per 100,000 adults, while annual unique 
incidence in patients 65+ years of age was 2,093 cases per 100,000 adults. 
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Community-acquired pneumonia incidence estimates have been observed to 
fluctuate by country in some instances. For example, the average rates were reported to be 
29.6 cases per 10,000 individuals in Germany in 2009, 15.9 cases per 10,000 individuals 
in Malaysia in 2016, 29.5 cases per 10,000 individuals in the Netherlands in 2015, 31.2 
cases per 10,000 individuals in the United Kingdom (UK) in 2016, and 8.1 cases per 10,000 
individuals in Vietnam in 2013, with incidence varying greatly by age group in a manner 
similar to the patterns observed in the EPIC study (11-13, 15, 16). It is quite possible that 
variations in age distribution of populations in different countries contributed to the 
differences seen in overall incidence rates. 
Risk for acquiring community-acquired pneumonia include several factors, such as 
being of older age, having comorbidities, certain lifestyle factors, and some environmental 
factors (17). Age is a factor of considerable importance when examining the risk of 
acquiring community-acquired pneumonia (18, 19). As demonstrated by the EPIC study, 
being in the elderly population – defined as 65 years of age or greater – results in a marked 
increase in incidence over prior age groups (6). A study published in 2018 analyzing 2014-
2015 Medicare claims data of elderly adults in the US noted that community-acquired 
pneumonia resulted in a higher incidence of hospitalization (846.7 hospitalizations per 
100,000 person-years) than myocardial infarction, osteoporotic fractures, and stroke, 
which resulted in 405, 343.9, and 278.9 hospitalizations per 100,000 person-years, 
respectively (20). 
Elderly individuals are at greater risk for community-acquired pneumonia due to a 
number of factors. First and foremost, the aging process results in certain impairments in 
immune and lung function over time, such as reduced efficiency of nasal mucociliary 
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clearance, chronic low-grade pulmonary inflammation, and decreased functionality of 
immune cells (21-24). Additionally, the elderly may begin to experience swallowing 
disorders, increasing risk for aspiration – a known risk factor of pneumonia (25). Age-
associated malnutrition, weight loss, general reduction in quality of life, and declines in 
physical functionality are also risk factors for community-acquired pneumonia (26-28). 
Finally, elderly individuals often incur a greater burden of comorbidities than those seen 
in younger age groups, many of which have been associated with community-acquired 
pneumonia (28). 
 The comorbidities associated with risk for community-acquired pneumonia are 
numerous, spanning various bodily systems. Chronic heart disease and respiratory 
conditions, including asthma, bronchitis, chronic obstructive pulmonary disease (COPD), 
and history of pneumonia, have been strongly associated with risk of community-acquired 
pneumonia (18, 19, 29-34). Cerebrovascular disease, such as stroke, and neurological 
conditions such as dementia, epilepsy, multiple sclerosis, and Parkinson’s disease have 
been linked to increased risk; elevated risk may occur due to swallowing disorders resulting 
from these conditions and sedative medications used to treat them, possibly resulting in 
aspiration (17). Conditions that result in immune system deficiencies or dysfunction, such 
as asplenia, cancer, human immunodeficiency virus (HIV) / acquired immunodeficiency 
syndrome (AIDS), and rheumatoid arthritis have been associated with increased risk (19, 
34, 35). Other conditions that have been associated with increased community-acquired 
pneumonia risk are anemia, chronic renal and liver disease, diabetes mellitus, dysphagia, 
and functional impairment (19, 34, 36). 
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 Several demographic and lifestyle factors have been associated with risk for 
community-acquired pneumonia. Some risk factors, such as having poor nutritional status 
(ex. underweight or malnutrition), having poor dental hygiene, and smoking, have been 
definitively linked to increased risk in the literature (19, 32, 33, 37). Others have been less 
consistent in their association; these risk factors include misuse of intravenous drugs, being 
overweight, being male, being unmarried/single, exposure to passive smoking, having high 
alcohol intake, and having regular contact with children (19, 32, 33, 38-41). The literature 
examining protective factors is  inconclusive, but some studies have shown that meeting 
daily physical exercise requirements, higher education level, and being vaccinated against 
influenza can reduce risk (42). The existing adult vaccine for Streptococcus pneumoniae 
has shown varied efficacy in numerous studies, with some studies showing a protective 
effect and others showing minimal efficacy (34, 43). 
 The literature examining community-acquired pneumonia risk as it relates to 
environmental factors is relatively sparse. An association between increased risk and 
occupational exposure to airborne contaminants such as asbestos and agricultural, coal, and 
stone dusts has been detected (44). Another study noted an association between increased 
risk with recent rapid changes in temperature in the occupational setting (32). It has been 
found that self-report of regular occupational exposure to gases, fumes, and chemicals and 
in-home exposure to fumes from gasoline, paints, and solvents has been associated with 
increased risk in individuals aged 65 years and older (19).  
A Canadian study published in 2009 observed that two-year exposure to nitrogen 
dioxide and PM2.5 in individuals aged 65 years and older was associated with significantly 
elevated odds of community-acquired pneumonia hospitalization, with odds ratios of 2.30 
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(95% CI: 1.25-4.21) for nitrogen dioxide and 2.26 (95% CI: 1.20-4.24) for PM2.5, adjusting 
for age, sex, education, smoking history, and history of exposure to workplace 
environmental contaminants (45). Participants were recruited from within the Hamilton 
catchment area in Ontario, Canada, with 345 patients hospitalized for community acquired 
pneumonia randomly recruited and 494 controls from the same community randomly 
recruited. Nitrogen dioxide and PM2.5 data were gathered from monitoring stations 
operated by the Ontario Ministry of Environment; participant address-specific ambient 
pollutant values were estimated using inverse distance weighting and bicubic splines 
methods, and also land use regression for nitrogen dioxide exclusively, though primary 
association results were reported using inverse distance weighting-based exposure values. 
Mortality from Community-Acquired Pneumonia 
 Community-acquired pneumonia associated mortality rates tend to be the highest 
among adults over the age of sixty-five years, with mortality rates ranging from 10% to 
30%, though elevated long term mortality rates have been observed even after adjusting 
for age (46, 47). Several chronic diseases and conditions have been associated with 
increased risk for mortality from community-acquired pneumonia, including 
cardiovascular disease, COPD, human immunodeficiency virus (HIV), malignant cancers, 
neurodegenerative disorders, and malnutrition (46, 48).  The number of factors implicated 
in the risk for community-acquired pneumonia mortality led to the development of a 
pneumonia severity index (PSI) to identify those at low risk for dying from the disease 
within thirty days of presentation (49) and to influence clinical care and management.  
PSI scores are based on the presence, or lack, of several variables that are known 
to be associated with community-acquired pneumonia mortality. The PSI score can range 
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from 0 to 395; point values vary by variable, and points are accumulated depending on 
selections made. These variables fall into several categories, including demographic 
factors, comorbidities, findings from physical examination, and findings from laboratory 
and radiographic examination. Demographic factors include increasing age, nursing home 
residence status, and male sex. Comorbidities include cerebrovascular disease, congestive 
heart failure, liver disease, neoplastic disease, and renal disease. Factors from physical 
examination include altered mental state status, pulse greater than or equal to 125 
heartbeats per minute, respiratory rate greater than or equal to 30 breaths per minute, 
systolic blood pressure less than 90 mmHg, and temperature less than 35 degrees Celsius 
or greater than or equal to 40 degrees Celsius. Risk factors from laboratory or radiographic 
examination include arterial pH less than 7.35, blood urea nitrogen greater than or equal to 
30 mg/dL, glucose greater than or equal to 250 mg/dL, hematocrit less than 30 percent, 
partial pressure of arterial oxygen less than 60 mmHg or oxygen saturation less than 90%, 
presence of pleural effusion, and sodium levels less than 130 mEq/L. 
 The adult PSI is categorized in to five classes, each of which represents a mortality 
risk range to which an individual is assigned (49). The classes are as follows: Class I (0-50 
points) indicates an estimated mortality risk of approximately 0.1%, Class II (51-70 points) 
indicates an estimated mortality risk of 0.7%, Class III (71-90 points) indicates an 
estimated mortality risk of 0.9%, Class IV (91-130 points) indicates an estimated mortality 
risk of 9.3%, and Class V (131-395 points) indicates an estimated mortality risk of 27%. 
Those falling into Classes I and II are at low risk for mortality and are generally referred 
to outpatient care. Those who fall into Class III are at moderate risk for mortality and may 
be either referred to outpatient care or admitted for observation. Classes IV and V are high 
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mortality risk classes, generally resulting in hospitalization for inpatient care. Though often 
cited as being a quality decision aid in pneumonia prognosis, it has been stated that the PSI 
should not be relied upon as the sole indicator for decision to hospitalize due to low positive 
predictive values (50, 51). 
Other comorbidities and conditions not included in the adult PSI have been 
associated with mortality from community-acquired pneumonia, including Barthel Index-
indicated functional status, chronic obstructive pulmonary disease (COPD) status, and 
ineffective antibiotic therapy (35, 52, 53). Additionally, there is a small body of evidence 
that suggests that environmental exposures such as air pollution can increase community-
acquired pneumonia associated mortality risk. A case-crossover study published in 2018 
found that short-term exposure to PM2.5 – within six days of outcome presentation –  was 
associated with increased hospitalization (lag day 1 adjusted odds ratio (AOR) per 10 ug/m3 
over 12 ug/m3: 1.35, 95% CI: 1.16-1.57) and mortality (lag day 5 AOR: 1.50, 95% CI: 
1.03-2.16) from pneumonia in individuals aged 65 years and older, based on results from 
4,336 pneumonia cases from seven hospitals in the Wasatch Front metropolitan area in 
Utah (54). Air pollutant data were derived from ten EPA air monitoring stations located in 
the same topographical basin as the corresponding participant. Participant address-specific 
values were interpolated using inverse distance weighting. An occupational study of 
Swedish construction workers noted that exposure to inorganic dusts, such as those from 
asbestos, cement, concrete, man-made mineral fibers, and quartz, was associated with 
increased mortality from community-acquired pneumonia (55). Additionally, higher levels 
of physical activity have been associated with reduced mortality from community-acquired 
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pneumonia and other respiratory conditions (56). Sequential rounds of antibiotic therapy 
have been shown to be protective, as well (52). 
Pneumonia and Particulate Matter 
Air pollution, including PM, has been increasingly recognized as a global health 
threat by the World Health Organization (WHO), who held the Global Conference on Air 
Pollution and Health at the end of October 2018 to discuss measures to combat this 
increasingly pervasive source of premature death (57). An ever-growing body of research 
has been compiled on the topic of respiratory outcomes and PM exposure, suggesting with 
relative uniformity that there exists a relationship between the two. Despite its status as a 
leading cause of death, pneumonia seems to make up a comparatively small percentage of 
these studies. Some evidence exists that associates environmental exposures such as air 
pollution with increased pneumonia mortality risk; however, likelihood of hospitalization 
is more often studied, and an association is well established (54, 58, 59).  
Particulate matter (PM) is a form of air pollution primarily categorized into 
different size fractions – typically PM10 and PM2.5 (60). PM10 can be defined as particles 
that are less than 10 micrometers in diameter. PM2.5, a subset of PM10, can be defined as 
particles that are 2.5 micrometers in diameter or smaller and are referred to as fine PM. 
Coarse PM is a category of PM where the particles are between 2.5 and 10 micrometers in 
diameter. The chemical compositions of these particles largely depend on their sources of 
origin, which can be both natural and anthropogenic (60, 61). Natural sources include soil, 
dust, minerals, sea salt, and bioaerosols; naturally-derived PM is typically larger, belonging 
to the classification PM10, while PM2.5 is often anthropogenically produced and commonly 
attributed to combustion processes, both anthropogenic and natural (62). Anthropogenic 
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sources include incomplete combustion processes, automobile emissions, dusts from 
agriculture and construction, and emissions from cooking (63). Due to their diminutive 
size, these particles are capable of traveling great distances through the air and are easily 
inhaled. Once inhaled, PM can penetrate deep into the lungs and bloodstream; the fraction 
of inhaled particles capable of penetrating beyond the larynx and unciliated airways are 
known as the thoracic and respirable fraction, respectively (64).  
National Ambient Air Quality Standards (NAAQS) are used by the US EPA to 
determine the cutoff points for maximum levels of unsafe exposure to criteria pollutants, 
which include airborne lead (Pb), carbon monoxide (CO), nitrogen dioxide (NO2) and nitric 
oxides (NOx), ozone (O3), PM10 and PM2.5, and sulfur dioxide (SO2). NAAQS are divided 
into primary and secondary standards (65). Primary standards are generally more stringent 
as they are designed to provide public health protection to both the general population and 
populations deemed to be at-risk or “sensitive,” such as those suffering from chronic 
respiratory conditions, children, and the elderly. Secondary standards can be – but are not 
always – less stringent and are put in place to protect the public welfare by reducing the 
likelihood of such events as reduced visibility and property and resource damage. The 
standard for PM10 is set to a twenty-four-hour average of 150 μg/m
3, which cannot be 
exceeded more than once per year on average over three years. PM2.5 has a primary standard 
set to a one-year average of 12.0 μg/m3, based upon the annual mean averaged over three 
years, a secondary standard set to a one-year average of 15.0 μg/m3, based upon the annual 
mean averaged over three years, and a  standard set to a twenty-four-hour average of 35 
μg/m3, based upon the 98th percentile averaged over three years. 
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Exposure to these particles has been associated with all-cause mortality, cause-
specific mortality, and morbidities, including cardiovascular and respiratory outcomes (63, 
66-69), with stronger associations for smaller PM size fractions. The study of PM’s 
influence on pneumonia incidence, mortality, and hospitalization has been complicated by 
the fact that seasonal climate seems to play a significant role on the magnitude of the 
observed associations. A case-crossover analysis including 1,384,813 pneumonia hospital 
admissions based on data from 1986 to 1999 in 36 US cities determined that ambient PM10 
levels, gathered using the US EPA’s Aerometric Retrieval System, were associated with 
increased hospitalization for pneumonia (69). The increase in pneumonia hospital 
admissions was higher by 0.84% (95% CI: 0.50% - 1.19%) for a 10 microgram per cubic 
meter (μg/m3) increase in PM10 at the time of hospital admission, adjusting for day of the 
week and apparent temperature. While PM10 levels generally remained consistent 
throughout the year, it was found that those cities with a higher summer apparent 
temperature and a greater percentage of homes containing central air conditioning 
experienced a lower increase in hospitalizations due to pneumonia, possibly due to the fact 
that those living in homes with central air conditioning would have lower outdoor air 
pollutant exposure within their homes than those relying on open windows for ventilation 
during warmer months. 
Another study by Qui et al., published in 2014, examined the relationship between 
exposure to PM10, PM2.5, and emergency hospital admissions due to pneumonia in Hong 
Kong, China (70), where pneumonia was the second leading cause of death that year. PM 
data were gathered from ten general monitoring stations throughout the region. The study 
included 75,863 hospital admissions for pneumonia spanning the period from January 1, 
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2011 to December 31, 2012.  Utilizing generalized additive Poisson modeling and 
unconstrained distributed lag modeling, it was found that for every 10 μg/m3 increase in 
PM10 over the previous four days, emergency hospitalizations increased by 3.33% (95% 
CI: 1.54% – 5.15%), adjusting for long-term trends, seasonality, weather factors, calendar 
effect, and influenza epidemics. Under the same conditions, it was found that for every 10 
μg/m3 increase in PM2.5 over the previous four days, emergency hospitalizations increased 
by 1.69% (95% CI: 0.68% – 2.70%). 
Air Pollution in Jefferson County, Kentucky 
Jefferson County, Kentucky (KY), is located in the northwest portion of the 
Commonwealth, and falls within the Ohio River Valley. The Ohio River Valley is known 
to contain a high number of pollutant-generating facilities, including coal-fired power 
plants, mining sites, and industrial sites (71). Attributed to the geographic characteristics 
of the Ohio River Valley, it has been shown that pollutants generated in the area become 
trapped during periods of meteorological high pressure, and are subsequently transported 
across the region when low pressure fronts move through (72). These regional 
characteristics suggest particulate matter to be a relevant exposure to study in relation to 
community-acquired pneumonia mortality in Jefferson County, KY.  
Despite being located within this region, in 2018, Jefferson County was reported to 
have met the majority of the EPA-mandated NAAQS for criteria pollutants (73). Of these 
pollutants, Jefferson County failed to meet the NAAQS in 2018 for only ozone, earning 
the designation of “non-attainment” status; failing to meet even one NAAQS is enough for 
a county to be placed in “non-attainment” status by the EPA. Sulfur dioxide levels were 
formerly in “non-attainment,” but have since fallen below the NAAQS, and “attainment” 
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re-designation is being petitioned by the Louisville Metro Air Pollution Control District 
(APCD). The Louisville Metro APCD works alongside the EPA, Kentucky Division for 
Air Quality, and Indiana Department of Environmental Management to implement and 
enforce air-related legislation, such as the Clean Air Act, in Jefferson County. 
Though Jefferson County air pollution generally falls within NAAQS parameters, 
it is possible that specific locations within the county, such as those closer to heavily 
trafficked roadways or point sources, may experience higher levels of PM exposure than 
those recorded at monitoring sites. Many individuals in this county rely upon motor 
vehicles to get to work. According to 2017 American Community Survey data, 293,791 
(80.2%) out of 366,473 surveyed Jefferson County workers aged sixteen years and over 
had access to at least one motor vehicle and used it to drive to work alone (74). A thorough 
satellite-level observation of the county revealed that a number of residential areas fall 
within a short distance of busy highways and other frequently driven roadways (75); 
automobile-generated PM exposure may be increased within these areas.  
Particulate Matter, Mortality, and Effect Modifiers 
 Effect modification occurs when a third variable, present on the proverbial pathway 
linking exposure and outcome, is introduced, and varyingly affects the outcome depending 
on the level, or stratum, of the third variable. Though perhaps not specific to pneumonia 
mortality as the outcome, there have been studies examining effect modification as it 
pertains to the relationship between PM exposure and general and cause-specific mortality. 
Among these studies, the variables age, sex, and presence of specific comorbidities, such 
as type 2 diabetes and cardiovascular disease, are commonly examined, suggesting in some 
cases that they serve as effect modifiers in the aforementioned relationship (76-79). 
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 Older age has been consistently associated with elevated mortality resulting from 
PM exposure in the literature. Individuals 85 years and older within the 2000-2012 US 
Medicare population were found to have significantly elevated relative risk of mortality 
associated with each 10 μg/m3 increase in PM2.5 (79, 80). A study of the residents of Oslo, 
Norway published in 2007 noted that both men and women at or above the age of 51 years 
who were exposed to higher levels of PM10 and PM2.5, indicated by exposure quartiles, had 
significantly elevated adjusted hazard ratios of all-cause and cause-specific mortality 
versus those observed in the referent lowest exposure quartile; significant trend p-values 
were consistently reported among PM quartiles as well (81). A 12-year population-based 
retrospective study carried out in Shenyang, China reported that both those over and under 
60 years of age had significantly elevated adjusted hazard ratios for mortality associated 
with a 10 μg/m3 increase in PM10 (≤60 years: AHR = 1.68, 95% CI = 1.52-1.86; >60 years: 
AHR = 1.66, 95% CI = 1.59-1.74), adjusting for age, gender, education level, smoking 
status, personal income, occupational exposure, BMI, and exercise (82). 
In more than one instance, females have been noted to have greater mortality risk 
from air pollution exposure than males (77-79). This result seems to be more closely tied 
to PM exposure than to other air pollutants. For example, females among the 2000-2012 
US Medicare population had a greater relative risk of mortality due to increased PM2.5 
exposure than males, but such an effect was not seen due to increased ozone exposure (79). 
The possibility that females may experience PM exposure differently from males has been 
examined in past literature. One such study, conducted in a laboratory setting, noted that 
female participants with otherwise normal respiratory health were found to have greater 
total and coarse particle deposition in the lungs versus male participants (83). Another 
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study noted that female marathon runners, but not male runners, had significantly reduced 
performance as a result of PM10 exposure, with performance being reduced by 
approximately 1.4% for every 10 μg/m3 increase in PM10 concentration present during 
events (84). 
Race less commonly appeared as an effect modifier in the literature but was present 
enough for it to warrant investigation. In one study, the geographic distribution of racial 
groups within an area ultimately reveals itself to be a cause for concern, with worse health 
outcomes revealed in predominately African American neighborhoods (85). African 
Americans have been found to have higher hospital mortality due to pneumonia than whites 
within the same hospital as well (86), and have also been found to have a significantly 
greater burden of PM exposure versus the general population (87). In the same 2000-2012 
US Medicare population previously mentioned, non-whites were borderline significantly 
more likely to have increased mortality as a result of increased PM2.5 exposure than whites 
(79) 
Mapping Air Pollution With GIS  
 Air pollution data used in research is commonly gathered from monitoring stations 
established throughout the locations of interest. In the US, the EPA maintains many such 
monitors across the country and makes the data freely and easily available through their 
website. Though offering a plethora of generalized information, the unfortunate downside 
to utilizing these resources is visible when, in certain parts of the country,  the number of 
monitors is sparse compared to the areas being monitored. For example, a single 
monitoring station may be rated for county-wide representation, but it still only reflects 
data from a given geographic point. This is not to say that the information gathered is 
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without use, but a single monitor fails to take into account localized variations in pollutant 
concentrations that may be crucial to understanding variability in air pollution across space 
that impact health outcomes in areas being studied. 
 Geographic Information Systems (GIS) provide a way to circumvent this issue 
through the use of spatial interpolation techniques. Several such techniques exist, ranging 
in complexity and ease of implementation (88). Spatial averaging is a technique in which 
the values for a given pollutant at a specified time are gathered from all monitors within a 
designated radius from the point of interest and are averaged, the result of which is assigned 
to a geocoded location (88). The nearest neighbor technique requires only that a point of 
interest be assigned the pollutant concentration value of its nearest monitoring site, which 
for some points may be quite close while for other points may be very far from the monitor 
(88). Inverse distance weighting involves the calculation of interpolation weights as a 
function of the distance between monitoring sites and the point of interest, with values 
provided by monitoring sites closer to the point of interest weighing more heavily than 
those further away (88). Kriging involves the smoothing of data from point measurements 
scattered across a geographic area, providing weights that can be used to determine values 
for a given variable (88, 89).  
Despite sharing some similarities in that distance is utilized by both methodologies, 
inverse distance weighting and Kriging are separate approaches. While kriging is 
geostatistical, inverse distance weighting is a deterministic interpolation method that 
suggests an inherent simplicity in how it is applied, whereas kriging uses statistical models 
and spatial autocorrelation is considered (90). Inverse distance weighting is more 
appropriately used when the variable value being interpolated is dependent on location and 
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the variable’s value is assumed to decrease as distance increases from the sampling 
location, while Kriging is best used when a spatially correlated distance or directional bias 
is known to exist in the data being examined (90, 91). Given that the air monitoring stations 
simply detect levels of air pollutants and are not sources of these pollutants, it is unlikely 
that the inverse distance weighting assumptions hold true, making it less suitable than the 
kriging interpolative method. Unfortunately, both inverse distance weighting and kriging 











 The primary objective of the study was to examine the relationship between 
exposure to airborne particulate matter at diagnosis and incidence of 30-day mortality 
among adults hospitalized with community-acquired pneumonia in Jefferson County, 
Kentucky. The study analyzed data from the Hospitalized Adults with Pneumococcal 
Pneumonia: Incidence Study (HAPPI) cohort based out of the University of Louisville 
Division of Infectious Diseases (UofL ID). Exposure values were interpolated using GIS 
spatial interpolation methods, which were largely reliant on data gathered by US EPA 
monitoring sites that were available online. 
Hypothesis 
 The hypothesis of this study is that higher exposure to PM10 and PM2.5 is associated 
with increased incidence of mortality among adults hospitalized for community-acquired 
pneumonia in Jefferson County, KY.  
Study Area and Population 
 The study area was Jefferson County in the Commonwealth of Kentucky, USA. 
The county covers an area of approximately 398 square miles. Based upon data from the 
2017 American Community Survey, the total population of the study area was 764,378 
people, 51.7% of which were female and 48.3% of which were male (92). The median age 
of Jefferson County residents was 38.0 years. Approximately 77.4% of the population was 
over the age of eighteen years. An estimated 14.9% of the population was over the age of 
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65 years. 72.3% of residents identified as White, 21.2% as Black or African American, 
2.7% as Asian, 0.1% as American Indian and Alaska Native, 2.8% as two or more races, 
and 0.8% as other race. 
 All HAPPI participants were recruited after being hospitalized in Jefferson County 
due to community-acquired pneumonia between June 1, 2014 and June 1, 2016. In total, 
6,176 participants were recruited. HAPPI participants included adults eighteen years of age 
or older hospitalized and diagnosed with community-acquired pneumonia at one of nine 
HAPPI-affiliated hospitals (Baptist East, Jewish Hospital, Norton Audubon, Norton 
Brownsboro, Norton Downtown, Norton Suburban, St. Mary and Elizabeth, University 
Hospital, or the Veterans Affairs (VA) Hospital) and who had a permanent home address 
and residence in Jefferson County. The addresses could not be PO Boxes or extended stay 
hotels. Participants were excluded from participation in HAPPI if they were in the 
corrections system, had an invalid Social Security Number, had missing vital status data, 
or were missing geocoded address data.  
Outcome 
 The outcome examined was all-cause mortality at or within thirty days. Mortality 
was reported at discharge from initial hospitalization, thirty days, six months, and one year, 
though only those who fell within the first two categories will be included in this analysis. 
Mortality was verified by the Kentucky Office of Vital Statistics through the release of 
limited death certificate information, which included confirmation and date of death but 
not cause. Due to monetary cost, cause of death information was not available for analysis. 
Mortality at or within thirty days was assumed to be most closely linked to pneumonia and 
therefore served as the proxy outcome of pneumonia-specific mortality; this was by 
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recommendation of a member of the committee, but also appears to be a common outcome 
when examining pneumonia-related outcomes (93, 94). 597 (9.7%) of participants had died 
at or within thirty days. Cause of death was only reported for 12 (0.20%) participants, 
which was attributed to the cost of acquiring this information, with 5 of those deaths 
attributed to respiratory complications. 
 Where survival time was needed for Cox proportional hazards regression, person-
time (days) was calculated by finding the difference between date of death and date of 
enrollment, as participants were enrolled at the time of hospitalization. Those who did not 
die were assumed to have the maximum amount of survival time – thirty days.  
Exposure 
 The primary exposures of interest were concentrations of PM10 and PM2.5 at 
hospital admission date. The sources of information for PM10 and PM2.5 were from EPA air 
monitoring sites operated by the Louisville Metro APCD throughout Jefferson County 
(Table 1) (95, 96). In 2014, PM2.5 concentration values were gathered by four monitoring 
sites located at Southwick (site ID – 211110043), Watson Lane (site ID – 211110051), 
Cannons Lane (site ID – 211110067), and Durrett Lane (site ID – 211110075); in 2014, 
PM10 concentration values were gathered by three monitoring sites located at Southwick, 
Wyandotte Park (site ID – 211110051), and Watson Lane, though the Wyandotte Park 
monitor only provided results early in the year and prior to the beginning of HAPPI 
recruitment. In 2015, PM2.5 concentration values were gathered by four monitoring sites 
located at Southwick, Watson Lane, Cannons Lane, and Durrett Lane; in this year, PM10 
concentration values were gathered by two monitoring sites located at Southwick and 
Watson Lane. In 2016, PM2.5 concentration values were gathered by four monitoring sites 
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located at Southwick, Watson Lane, Cannons Lane, and Durrett Lane; in this year, PM10 
concentration values were gathered by two monitoring sites located at Southwick and 
Watson Lane. Data from these sites were generally reported every one to three days and 
are available for download through the EPA’s website (96). Concentration values are 
recorded in units of microgram per cubic meter (μg/m3). See Figures 1 and 2 for mapped 
monitor locations within Jefferson County. 
 
Table 1: Particulate matter (PM) data provided by corresponding Jefferson County monitoring 
station, 2014-2016 
Monitoring Station 2014 2015 2016 
Southwick PM2.5, PM10 PM2.5, PM10 PM2.5, PM10 
Watson Lane PM2.5, PM10 PM2.5, PM10 PM2.5, PM10 
Cannons Lane PM2.5 PM2.5 PM2.5 
Durrett Lane PM2.5 PM2.5 PM2.5 
Wyandotte Park PM10   









Figure 2 - PM2.5 monitoring station locations within Jefferson County, 2014-2016. 
 
 PM10 and PM2.5 concentration values for geocoded participant addresses at the time 
of hospitalization were interpolated through the use of two different spatial methodologies: 
spatial averaging and Kriging.  
Covariates 
Demographic Variables 
 To better assess the relationship between air pollution exposure and mortality, 
several demographic variables were adjusted for including age, sex, and race. These 
variables were possible predictors of pneumonia-specific mortality. Age, sex, and race 
information were collected from electronic medical records. Age was defined in years and 
primarily presented as a continuous variable; where represented in categories, age 
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categories were established as individuals 18-64 years and individuals 65 years and older. 
Sex was defined as female and male. Race was defined as black, white, and other. 
Other Variables 
 Other variables considered for adjustment were those associated with community-
acquired pneumonia mortality, including PSI classification, active intravenous drug use 
status, alcoholic status, intensive care unit transfer status at time of initial hospitalization, 
past thirty-days oral antimicrobial therapy receival status, past ninety-days intravenous 
antibacterial therapy receival status, pneumococcal vaccine receival status, seasonal 
influenza vaccine receival status, smoking status, suspected aspiration status, and 
ventilatory support requirement status at time of initial hospitalization. Variable data were 
collected from, or calculated using, electronic medical records.  
Participant PSI values represented the cumulative effect of all variables represented 
by this value and were defined as classes I through V. Active intravenous drug use status, 
alcoholic status, intensive care unit transfer status, past thirty-day oral antimicrobial 
therapy receival status,  past ninety-day intravenous antibacterial therapy receival status, 
pneumococcal vaccine receival status, and seasonal influenza vaccine receival status are 
defined as yes or no. Smoking status was defined as either being a current smoker, having 
past history of smoking, or having never been a smoker. Suspected aspiration status was 




General Statistical Methods 
Categorical demographic characteristics and other covariates were cross tabulated 
by dichotomous mortality status variables (i.e. death within thirty days), and were 
compared using Chi-square tests of independence.  
 Univariate and regression results were reported as significant when alpha was less 
than 0.05 (p < 0.05). 95% confidence intervals (CI) were also reported. The presence of 
extreme outliers among the exposure data was investigated, with extreme outliers identified 
as being those values that were (3.0 x IQR) below the first quartile or above the third 
quartile; outliers identified in this fashion were removed. Multicollinearity was assessed 
by examining tolerance and variance inflation factors, with the tolerance cutoff set at less 
than 0.2 and variation inflation factor cutoff at greater than 4.0. In instances where 
correlation among categorical variables was examined, the coefficient Cramer’s V was 
utilized, where strength of association was determined by values that fall on a scale of 0 
(no association) to 1 (perfect association); strength of association scale was approximately 
as follows: 0.00-0.10 suggests no relationship or lack of useful information, 0.10-0.20 
suggests a weak association, 0.20-0.25 suggests an association of moderate strength, 0.25-
0.30 suggests a moderately strong association, 0.30-0.35 suggests a strong association, 
0.35-0.40 suggests a very strong association, 0.40-0.45 suggests an extremely strong 
association that may be indicative of measurement of the same concept, and >0.45 suggests 
redundancy in that the variables being examined are likely measuring the same concept 
(97). Statistical analyses were carried out using SAS statistical software. GIS-related 
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functions were carried using Esri ArcGIS (ArcMap version 10.6.1). The map projection 
for ArcGIS functions was the geographic coordinate system NAD 1983 (2011).  
Aim One Statistical Methods 
 Continuous PM10 and PM2.5 data were examined for normality using the Anderson-
Darling test for normality. Continuous PM10 and PM2.5 data at hospital admission date were 
compared against mortality status using nonparametric Wilcoxon rank-sum tests, as they 
were not normally distributed. Additionally, both PM variables were analyzed as 
dichotomous values using their corresponding twenty-four hour NAAQS means as cutoff 
points, and as quartiles, and compared against mortality status using Chi-square tests, or 
Fisher’s exact test where appropriate. Covariates were cross-tabulated by quartile of PM 
exposure to examine the association between covariate categories and level of exposure. 
Analyses were conducted using interpolated PM data based on the geospatial techniques 
spatial averaging. 
 The spatial averaging technique utilized the PM values detected by each active 
monitoring station within the study area at the day of participant diagnosis. These values 
were averaged and the resulting values were attributed to the participant as their exposure. 
We considered a log-transformation of spatially averaged PM to improve normality; 
however, associations did not change substantially. 
 The relationship between PM exposure and mortality during hospitalization or 
within thirty days was analyzed using crude and multivariable logistic regression. The 
covariates included in this analysis were chosen based upon their known relevance in the 
existing literature, as outlined in the Introduction. Covariates were considered confounders 
if they are independently associated with exposure and outcome, and were not on the causal 
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pathway; determination was achieved by stratifying covariates by outcome and by 
exposure, placing the resulting values in tables, and examining the relationships, in addition 
to examining the impact of covariate inclusion on reported relationships. Non-confounders 
that appeared to have an association with the outcome were included as predictors; this was 
determined based on observed associations with the outcome in the covariate/outcome 
table created, and by examining significance of p-values from the univariate results therein. 
Strong predictors were those predictors that were perceived as being highly related to the 
outcome based upon the results of the covariate/outcome table created. Multiple models 
were presented: a minimally adjusted model containing only confounders, a partially 
adjusted model containing both confounders and strong predictors, and a fully adjusted 
model containing confounders and all predictors. 
A similar process was implemented to analyze the aforementioned relationship 
using Cox proportional hazards regression. Survival time (person/days) was calculated by 
finding the difference between participant date of death and participant enrollment date; 
participant enrollment date corresponds with date of hospitalization. Both regression types 
were included due to the fact that they ultimately examine different outcomes, despite 
yielding results that can be interpretted in a similar manner. The logistic regression in this 
analysis examined a pre-coded dichotomous outcome within the dataset that acted as a 
proxy for mortality associated with CAP; the Cox proportional hazards regression in this 
analysis examined time to death, based upon the presence of a death date for those 
participants who manifested the outcome and calculated survival time. 
 Where PM exposure was examined as quartiles, a p-value of trend was calculated 
to determine if a significant trend existed between quartiles of a given PM type (e.g, PM10). 
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To accomplish this, a dummy variable was created with four different levels, or levels one 
through four, with each level representing a numerically corresponding quartile. The 
median PM value for each numerically corresponding quartile was attributed to the 
appropriate level in the dummy variable; for example, the median value of PM10 within 
quartile one was attributed to all participants within quartile one, and therefore level one 
of the dummy variable. Within the regression models, the dummy variable was run in place 
of the quartile exposure and the resulting p-value of trend was noted. 
Aim Two Statistical Methods 
 Interpolation by the Kriging technique was achieved using the ArcGIS Kriging 
feature under the available Spatial Analyst toolbar, utilizing the relevant PM values from 
each monitor within the study area for the given day and the location of the monitor as the 
location of the point value, as localized PM measurements for each participant address 
were not available. Ordinary Kriging was used, as the mean of the point values was not 
assumed to be constant over the study area. The feasablity of kriging as a valid technique 
given data availability constraints will be examined. Example kriging models were 
generated for ten dates at different points in time (June 1-5, 2014 and December 1-5, 2014) 
to examine model feasibility, usefulness, and variability; these characteristics were 
examined by asking such questions as “what do model distributions look like,” “are 
observed patterns reliable, and “does Kriging appear to function properly given the sparsity 
of data available.” 
Aim Three Statistical Methods 
The potential presence of effect modification was also of interest, and was 
examined for age, race, and sex. Though specific comorbidities may also be effect 
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modifiers, the use of the generalized PSI covariate including such information rather than 
individual comorbidity statuses removed the ability to examine effect modification as a 
result of specific comorbidities within this study. The presence of significant effect 
modification was determined using the likelihood ratio test (LRT), comparing the standard 
partially adjusted model for the PM exposure type against the partially adjusted model 
containing the exposure / potential effect modifier interaction term. Effect modification 
analysis was performed on partially adjusted logistic regression models for all variations 
of exposure; this model was more parsimonious than the full model while still containing 
all covariates of interest. Where determined to be relevant, further examination of 
significant associations was pursued, including examination of relative risk among specific 











 The following are the results of the statistical analyses carried out during this 
project, broken down by their corresponding specific aim and exposure data group to which 
they belong, when relevant. 
Preliminary Analysis 
In total, data for 8,284 participants were present in the dataset received. Within the 
dataset, 2,088 participants did not belong to HAPPI, and were therefore not included, 
leaving the data of 6,176 participants to be analyzed. The exposure variable “PM10” was 
missing 8 values, and the exposure variable “PM2.5” was missing 1 value. The outcome 
variable “mortality within thirty days” was missing 2 values. Those missing outcome and 
exposure values were excluded, resulting in a total of 8 participants being removed from 
the analysis. An additional 23 participants were removed due to the detection of extreme 
outlier exposure data. Missing values for covariates within the sample are as follows: 1 
missing value for “suspicion of aspiration at time of hospitalization,” 5 missing values for 
“received oral antimicrobial therapy within the past 30 days,” 107 missing values for 
“received pneumococcal vaccination at or prior to time of hospitalization,” and 118 missing 
values for “received seasonal influenza vaccine at or prior to time of hospitalization.” 
Those with missing values attributed to covariates were classified as “missing” and 
included in the analysis. 
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A total of 6,145 participants were included in this analysis, after the removal of 
missing exposure and outcome values. Their characteristics are presented in Table 2. Of 
the 6,145 participants, 46.5% were male and 53.5% were female. The mean age of the 
study sample was 65.9 years, with a standard deviation of 16.5. 84.1% were above the age 
of 50 years, and 55.9% were at or above the age of 65 years. 79.3% identified as White, 
20.2% as Black, and 0.5% as Other. A large portion of the study sample was at moderate 
to high risk of pneumonia-associated mortality, with 18.7% falling into PSI Risk Class III, 
35.6% into Risk Class IV, and 22.9% into Risk Class V. 
Table 2: Descriptive statistics of HAPPI population by mortality within thirty days of hospital admission 
Variables Total Mortality p Valuec 





Mean age at enrollment, years (SD) 65.9 (16.5) 75.3 (13.6) 64.9 (16.5) <0.0001 
Sex    0.0012 
Female 3288 (53.5) 282 (47.2) 3006 (54.2)  
Male 2857 (46.5) 315 (52.8) 2542 (45.8)  
Race    <0.0001 
Black 1241 (20.2) 74 (12.4) 1167 (21.0)  
White 4872 (79.3) 522 (87.4) 4350 (78.4)  
Other 32 (0.5) 1 (0.2) 31 (0.6)  
PSId class    <0.0001 
Class I 393 (6.4) 4 (0.7) 389 (7.0)  
Class II 1007 (16.4) 9 (1.5) 998 (18.0)  
Class III 1149 (18.7) 32 (5.4) 1117 (20.1)  
Class IV 2187 (35.6) 193 (32.3) 1994 (36.0)  
Class V 1409 (22.9) 359 (60.1) 1050 (18.9)  
Direct transfer to ICUd upon hospital 
admission 
   <0.0001 
Yes 998 (16.2) 201 (33.7) 797 (14.4)  
No 5147 (83.8) 396 (66.3) 4751 (85.6)  
Received intravenous antibiotic therapy 
within the past 90 days 
   <0.0001 
Yes 1009 (16.4) 146 (24.5) 863 (15.6)  
No 5136 (83.6) 451 (75.5) 4685 (84.4)  
Received oral antimicrobial therapy 
within the past 30 days 
   0.6802 
Yes 1280 (20.8) 129 (21.6) 1151 (20.7)  
No 4860 (79.1) 468 (78.4) 4392 (79.2)  
Missing 5 (0.1) 0 (0.0) 5 (0.1)  
Alcoholic status    0.3098 
Yes 344 (5.6) 28 (4.7) 316 (5.7)  
No 5801 (94.4) 569 (95.3) 5232 (94.3)  
Active intravenous drug use status    0.0418 
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Yes 89 (1.5) 3 (0.5) 86 (1.5)  
No 6056 (98.5) 594 (99.5) 5462 (98.5)  
Smoking history    <0.0001 
Current smoker 2038 (33.2) 121 (20.3) 1917 (34.5)  
Past smoker 2419 (39.4) 288 (48.2) 2131 (38.4)  
Non-smoker 1688 (27.4) 188 (31.5) 1500 (27.1)  
Suspicion of aspiration at time of 
hospitalization 
   <0.0001 
Yes 622 (10.1) 123 (20.6) 499 (9.0)  
No 5522 (89.9) 474 (79.4) 5048 (91.0)  
Missing 1 (0.0) 0 (0.0) 1 (0.0)  
Required ventilatory support at time of 
initial hospitalization 
   <0.0001 
Yes 808 (13.2) 157 (26.3) 651 (11.7)  
No 5337 (86.8) 440 (73.7) 4897 (88.3)  
Received pneumococcal vaccination at or 
prior to time of hospitalization 
   0.0226 
Yes 3356 (54.6) 301 (50.4) 3055 (55.1)  
No 2685 (43.7) 290 (48.6) 2395 (43.2)  
Missing 104 (1.7) 6 (1.0) 98 (1.7)  
Received seasonal influenza vaccine at or 
prior to time of hospitalization 
   0.0138 
Yes 2906 (47.3) 257 (43.0) 2649 (47.7)  
No 3124 (50.8) 334 (55.9) 2790 (50.3)  
Missing 115 (1.9) 6 (1.0) 109 (2.0)  
a: Percentages (%) as percent of total column N 
b: Percentages (%) as percent of total column n 
c: Chi-square / Fisher exact / Wilcoxon rank sum p-value for comparison between mortality status categories 
d: PSI – pnemonia severity index, ICU – intensive care unit 
 
Aim One 
Analysis – Spatial Averaging Data 
Continuous PM10 and PM2.5 data were determined to be non-normally distributed 
using the Anderson-Darling test (p = <0.0050 for both). Log transforming the PM values 
did not result in the achievement of statistical normalcy (p = <0.0050 for both). Preliminary 
univariate analysis was conducted using the nonparametric Wilcoxon rank-sum test; results 
for both PM10 and PM2.5 were not significant, with determined p-values being 0.3008 and 
0.2361, respectively. The median PM10 value was found to be 15.00 μg/m
3 (IQR = 10.67). 
The median PM2.5 value was found to be 9.67 μg/m
3 (IQR = 6.29). PM10 and PM2.5 
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distributions can be viewed in Figures 3 and 4. Log transformed PM10 and PM2.5 


























Figure 3 - Distribution of spatially averaged continuous PM10 (μg/m3) concentrations at the time of 
hospitalization across the study sample. 
 
 
Figure 4 - Distribution of spatially averaged continuous PM2.5 (μg/m3) concentrations at the time of 





Figure 5 - Distribution of spatially averaged continuous, log-transformed PM10 concentrations at the 
time of hospitalization across the study sample. 
 
 
Figure 6 - Distribution of spatially averaged continuous, log-transformed PM2.5 concentrations at the 




Analysis of dichotomous PM10 exposure using the corresponding twenty-four hour 
NAAQS means cutoff point could not be carried out, as no PM10 values exceeded the cutoff 
point. This was noted even prior to the removal of extreme outliers. Analysis of 
dichotomous PM2.5 exposure using the corresponding twenty-four hour NAAQS means 
cutoff point could not be carried out, as no PM2.5 values exceeded the cutoff point.  
We calculated PM quartiles. The PM10 quartile ranges were established as follows: 
less than or equal to 9.67 μg/m3, greater than 9.67 μg/m3 and less than or equal to 15.00 
μg/m3, greater than 15.00 μg/m3 and less than or equal to 20.50 μg/m3, and greater than 
20.50 μg/m3. The PM2.5 quartile ranges were established as follows: less than or equal to 
7.07 μg/m3, greater than 7.07 μg/m3 and less than or equal to 9.63 μg/m3, greater than 9.63 
μg/m3 and less than or equal to 13.37 μg/m3, and greater than 13.37 μg/m3. Univariate 
analysis of quartiles by mortality status can be viewed in Table 3 and Table 4. Neither 
PM10 nor PM2.5 quartile variables were found to be statistically significant (p = 0.7232 and 
p = 0.4093, respectively) in univariate analysis. Those located within the highest PM10 
quartile had a slightly greater percentage of outcome occurrence versus those in lesser 
quartiles. Those located in the top two PM2.5 quartiles had a slightly greater percentage of 
outcome occurrence versus those in the lower two quartiles. 
Cross tabulation of covariates by quartile of PM10 and PM2.5 can be viewed in 
Tables 5 and 6. Those in the highest PM10 quartile contained a greater proportion of males, 
individuals requiring ventilatory support at time of hospitalization, individuals having 
required IV antimicrobrial therapy in the previous 90 days, active intravenous drug users, 
current smokers, individuals at risk for aspiration, and individuals who did not receive 
either the seasonal influenza or pneumoccocal vaccinations, as compared against the lowest 
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quartile. Proportions of individuals were generally similar in terms of racial distribution, 
ICU direct transfer status, and non-smoker status across quartiles. Observed PM2.5 patterns 
were quite similar to PM10 quartile patterns overall, though slightly reduced in their 
perceived magnitude. 
Table 3: Quartiles (PM10) by mortality at thirty days 
Variables Total Mortality p Valuec 





Quartile    0.7232 
1 (≤ 9.67 μg/m3) 1490 (24.2) 136 (22.8) 1354 (24.4)  
2 (> 9.67 μg/m3 and ≤ 15.00 
μg/m3) 
1590 (25.9) 156 (26.1) 1434 (25.8)  
3 (> 15.00 μg/m3 and ≤ 20.50 
μg/m3) 
1527 (24.9) 146 (24.5) 1381 (24.9)  
4 (> 20.50 μg/m3) 1538 (25.0) 159 (26.6) 1379 (24.9)  
a: Percentages (%) as percent of total column N 
b: Percentages (%) as percent of total column n 
c: Chi-square p-value for comparison between mortality status categories 
 
Table 4: Quartiles (PM2.5) by mortality at thirty days 
Variables Total Mortality p Valuec 





Quartile    0.4093 
1 (≤ 7.07 μg/m3) 1530 (24.9) 134 (22.4) 1396 (25.2)  
2 (> 7.07 μg/m3 and ≤ 9.63 
μg/m3) 
1536 (25.0) 148 (24.8) 1388 (25.0)  
3 (> 9.63 μg/m3 and ≤ 13.37 
μg/m3) 
1546 (25.2) 163 (27.3) 1383 (24.9)  
4 (> 13.37 μg/m3) 1533 (25.9) 152 (25.5) 1381 (24.9)  
a: Percentages (%) as percent of total column N 
b: Percentages (%) as percent of total column n 









Table 5: Descriptive statistics of HAPPI population by quartile of PM10 exposure at time of 
hospitalization (N = 6145) 
Variable Quartile 1 
(≤ 9.67 μg/m3) 
Quartile 2 
(> 9.67 μg/m3 
and ≤ 15.00 
μg/m3) 
Quartile 3 
(> 15.00 μg/m3 
and ≤ 20.50 
μg/m3) 
Quartile 4 
(> 20.50 μg/m3) 
Number of 
Participants 
n = 1490 n = 1590 n = 1527 n = 1538 
Mean age at 
enrollment, years (SD) 
65.8 (16.1) 66.8 (16.3) 65.7 (16.8) 65.3 (16.8) 
Sex, n (%)     
Female 807 (54.2) 859 (54.0) 831 (54.4) 791 (51.4) 
Male 683 (45.8) 731 (46.0) 696 (45.6) 747 (48.6) 
Race, n (%)     
Black 317 (21.3) 312 (19.6) 284 (18.6) 328 (21.3) 
White 1164 (78.1) 1269 (79.8) 1234 (80.8) 1205 (78.4) 
Other 9 (0.6) 9 (0.6) 9 (0.6) 5 (0.3) 
PSI class, n (%)     
Class I 82 (5.5) 94 (5.9) 106 (7.0) 111 (7.2) 
Class II 266 (17.8) 259 (16.3) 249 (16.3) 233 (15.1) 
Class III 278 (18.7) 307 (19.3) 277 (18.1) 287 (18.7) 
Class IV 532 (35.7) 564 (35.5) 538 (35.2) 553 (36.0) 
Class V 332 (22.3) 366 (23.0) 357 (23.4) 354 (23.0) 
Direct transfer to ICU 
upon hospital 
admission, n (%) 
    
Yes 248 (16.6) 238 (15.0) 261 (17.1) 251 (16.3) 
No 1242 (83.4) 1352 (85.0) 1266 (82.9) 1287 (83.7) 
Received intravenous 
antibiotic therapy 
within the past 90 
days, n (%) 
    
Yes 236 (15.8) 273 (17.2) 243 (15.9) 257 (16.7) 
No 1254 (84.2) 1317 (82.8) 1284 (84.1) 1281 (83.3) 
Received oral 
antimicrobial therapy 
within the past 30 
days, n (%) 
    
Yes 320 (21.5) 336 (21.1) 325 (21.3) 299 (19.4) 
No 1169 (78.5) 1253 (78.8) 1201 (78.6) 1237 (80.5) 
Missing 1 (0.0) 1 (0.1) 1 (0.1) 2 (0.1) 
Alcoholic status, n (%)     
Yes 96 (6.4) 83 (5.2) 77 (5.0) 88 (5.7) 
No 1394 (93.6) 1507 (94.8) 1450 (95.0) 1450 (94.3) 
Active intravenous 
drug use status, n (%) 
    
Yes 14 (0.9) 23 (1.4) 28 (1.8) 24 (1.6) 
No 1476 (99.1) 1567 (98.6) 1499 (98.2) 1514 (98.4) 
Smoking history, n (%)     
Current 
smoker 
486 (32.6) 531 (33.4) 507 (33.2) 514 (33.4) 
Past smoker 597 (40.1) 626 (39.4) 591 (38.7) 605 (39.3) 
Non-smoker 407 (27.3) 433 (27.2) 429 (28.1) 419 (27.3) 
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Suspicion of aspiration 
at time of 
hospitization, n (%) 
    
Yes 143 (9.6) 172 (10.8) 146 (9.6) 161 (10.5) 
No 1347 (90.4) 1418 (89.2) 1381 (90.4) 1376 (89.5) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.0) 
Required ventilatory 
support at time of 
initial hospitalization, 
n (%) 
    
Yes 198 (13.3) 198 (12.4) 199 (13.0) 213 (13.8) 
No 1292 (86.7) 1392 (87.6) 1328 (87.0) 1325 (86.2) 
Received 
pneumococcal 
vaccination at or prior 
to time of 
hospitalization, n (%) 
    
Yes 818 (54.9) 894 (56.2) 839 (54.9) 805 (52.3) 
No 652 (43.8) 675 (42.5) 663 (43.4) 695 (45.2) 
Missing 20 (1.3) 21 (1.3) 25 (1.7) 38 (2.5) 
Received seasonal 
influenza vaccine at or 
prior to time of 
hospitalization, n (%) 
    
Yes 819 (55.0) 807 (50.7) 713 (46.7) 567 (36.9) 
No 649 (43.5) 759 (47.7) 787 (51.5) 929 (60.4) 















Table 6: Descriptive statistics of HAPPI population by quartile of PM2.5 exposure at time of 
hospitalization (N = 6145) 
Variable Quartile 1 
(≤ 7.07 μg/m3) 
Quartile 2 
(> 7.07 μg/m3 
and ≤ 9.63 
μg/m3) 
Quartile 3 
(> 9.63 μg/m3 
and ≤ 13.37 
μg/m3) 
Quartile 4 
(> 13.37 μg/m3) 
Number of 
Participants 
n = 1530 n = 1536 n = 1546 n = 1533 
Mean age at 
enrollment, years (SD) 
66.2 (15.9) 65.9 (16.6) 66.1 (16.8) 65.6 (16.7) 
Sex, n (%)     
Female 827 (54.1) 808 (52.6) 837 (54.1) 816 (53.2) 
Male 703 (45.9) 728 (47.4) 709 (45.9) 717 (46.8) 
Race, n (%)     
Black 302 (19.7) 322 (21.0) 315 (20.4) 302 (19.7) 
White 1219 (79.7) 1203 (78.3) 1225 (79.2) 1225 (79.9) 
Other 9 (0.6) 11 (0.7) 6 (0.4) 6 (0.4) 
PSI class, n (%)     
Class I 77 (5.0) 103 (6.7) 105 (6.8) 108 (7.0) 
Class II 262 (17.1) 261 (17.00) 246 (15.9) 238 (15.5) 
Class III 284 (18.6) 286 (18.6) 294 (19.0) 285 (18.6) 
Class IV 545 (35.6) 531 (34.6) 541 (35.0) 570 (37.2) 
Class V 362 (23.7) 355 (23.1) 360 (23.3) 332 (21.7) 
Direct transfer to ICU 
upon hospital 
admission, n (%) 
    
Yes 238 (15.6) 251 (16.3) 259 (16.7) 250 (16.3) 
No 1292 (84.4) 1285 (83.7) 1287 (83.3) 1283 (83.7) 
Received intravenous 
antibiotic therapy 
within the past 90 
days, n (%) 
    
Yes 253 (16.5) 232 (15.1) 264 (17.1) 260 (17.0) 
No 1277 (83.5) 1304 (84.9) 1282 (82.9) 1273 (83.0) 
Received oral 
antimicrobial therapy 
within the past 30 
days, n (%) 
    
Yes 331 (21.6) 296 (19.3) 342 (22.1) 311 (20.3) 
No 1199 (78.4) 1237 (80.5) 1203 (77.8) 1221 (79.6) 
Missing 0 (0.0) 3 (0.2) 1 (0.1) 1 (0.1) 
Alcoholic status, n (%)     
Yes 106 (6.9) 75 (4.9) 85 (5.5) 78 (5.1) 
No 1424 (93.1) 1461 (95.1) 1461 (94.5) 1455 (94.9) 
Active intravenous 
drug use status, n (%) 
    
Yes 22 (1.4) 19 (1.2) 24 (1.5) 24 (1.6) 
No 1508 (98.6) 1517 (98.8) 1522 (98.5) 1509 (98.4) 
Smoking history, n (%)     
Current 
smoker 
520 (34.0) 511 (33.3) 493 (31.9) 514 (33.5) 
Past smoker 611 (39.9) 586 (38.1) 630 (40.7) 592 (38.6) 




aspiration at time of 
hospitization, n (%) 
    
Yes 144 (9.4) 159 (10.3) 161 (10.4) 158 (10.3) 
No 1386 (90.6) 1376 (89.6) 1385 (89.6) 1375 (89.7) 
Missing 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 
Required ventilatory 
support at time of 
initial hospitalization, 
n (%) 
    
Yes 185 (12.1) 204 (13.3) 211 (13.6) 208 (13.6) 
No 1345 (87.9) 1332 (86.7) 1335 (86.4) 1325 (86.4) 
Received 
pneumococcal 
vaccination at or prior 
to time of 
hospitalization, n (%) 
    
Yes 843 (55.1) 859 (55.9) 826 (53.4) 828 (54.0) 
No 652 (42.6) 657 (42.8) 690 (44.7) 686 (44.7) 
Missing 35 (2.3) 20 (1.3) 30 (1.9) 19 (1.3) 
Received seasonal 
influenza vaccine at or 
prior to time of 
hospitalization, n (%) 
    
Yes 747 (48.8) 750 (48.8) 711 (46.0) 698 (45.5) 
No 746 (48.8) 764 (49.7) 803 (51.9) 811 (52.9) 
Missing 37 (2.4) 22 (1.5) 32 (2.1) 24 (1.6) 
 
 The associations between covariates related to participant hospital stay or medical 
attention received (e.g., direct transfer to ICU status and receival of intravenous antibiotics 
within the past 90 days status, receival of oral antimicrobial therapy in the past 30 days 
status, requirement of ventilatory support at time of hospitalization status, receival of 
pneumococcal vaccine at or prior to hospitalization status, receival of seasonal influenza 
vaccine at or prior to hospitalization status)were examined. Receival of intravenous 
antibiotics within the past 90 days and receival of oral antimicrobial therapy within the past 
30 days were significantly associated (Chi-Square, p = <0.0001), but the association was 
fairly weak (5.1% “yes/yes” and 67.8% “no/no”; Cramer’s V = 0.1151). Direct transfer to 
ICU and both receival of oral antimicrobial therapy within the past 30 days and receival of 
intravenous antibiotics in the past 90 days were significantly associated (Chi-Square, p = 
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<0.0001), though these associations were also noted to be weak (2.5% “yes/yes” / 65.4% 
“no/no” and 3.4% “yes/yes” / 70.8% “no/no,” respectively; Cramer’s V = 0.0553 and 
0.0549, respectively). Requirement of ventilatory support at time of hospitalization was 
found to be significantly and strongly associated with direct transfer to ICU (9.1% 
“yes/yes” / 80.0% “no/no”; Chi-Square, p = <0.0001, Cramer’s V = 0.5624), suggesting 
the two variables were possibly measuring the same concept; the former was chosen to be 
removed from further analysis to enhance parsimony. Direct transfer to ICU was 
significantly associated with receival of the seasonal influenza vaccine (Chi-Square, p = 
0.0067) and not significantly associated with receival of the pneumococcal vaccine (Chi-
Square, p = 0.2295), but associations were weak in both situations (7.1% “yes/yes” / 41.9% 
“no/no” and 8.7% “yes/yes” / 43.3% “no/no,” respectively; Cramer’s V = 0.0404 and 
0.0219, respectively). It is worth noting that no multicollinearity was detected among the 
covariates chosen for further analysis. 
 Review of results viewable in Table 2 and Tables 5-6 were used to determine the 
presence of confounders, predictors, and strong predictors relating to the relationship 
between PM10 exposure and the outcome. The following covariates were determined to be 
confounders: age at enrollment, sex, receival of pneumococcal vaccine, receival of 
seasonal influenza vaccine. The following covariates were determined to be strong 
predictors: race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy with 
the past 90 days, smoking history, and suspicion of aspiration. The following covariate was 
determined to be a weak predictor: active intravenous drug use status. Confounders, 
predictors, and strong predictors were the same for the relationship between PM2.5 exposure 
and the outcome. 
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 As mentioned, these confounder/predictor determinations were based on 
observations drawn from the aforementioned tables. Consider the following observations 
based upon Table 2 and Table 5. The following observations are relevant to variables 
determined to be confounders, meaning they appeared to be related to both exposure and 
outcome. Mean age in years was higher in those with the outcome than those without (75.3 
versus 64.9), and though variation was generally limited between exposure quartiles, 
enough fluctuation was present that the variable was considered to be a confounder as a 
matter of best practice, given the far-reaching implications of age. A greater percentage of 
males experienced the outcome than females (52.8% among males versus 47.2% among 
females), and percentage variation between exposure quartiles was evident for both males 
(e.g., Q1 = 45.8% versus Q4 = 48.6%) and females (e.g., Q1 = 54.2% versus Q4 = 51.4%). 
Those who received the pneumococcal vaccine appeared to experience the outcome 
comparatively less as a proportion than those who did not (received the vaccine: yes = 
50.4% versus no = 55.1%; did not receive the vaccine: yes = 48.6% versus no = 43.2%), 
and percentage variation between exposure quartiles was present for both those who 
received the vaccine (e.g., Q1 = 54.9% versus Q4 = 52.3%) and those who did not (e.g., 
Q1 = 43.8% versus Q4 = 45.2%). Those who received the seasonal influenza vaccine also 
appeared to experience the outcome comparatively less as a proportion than those who did 
not (received the vaccine: yes = 43.0% versus no = 47.7%; did not receive the vaccine: yes 
= 55.9% versus no = 50.3%), and percentage variation between exposure quartiles was 
present for both those who received the vaccine (e.g., Q1 = 55.0% versus Q4 = 36.9%) and 
those who did not (e.g., Q1 = 43.5% versus Q4 = 60.4%). Variables determined to be 
predictors lacked clear variation between exposure quartiles, but still maintained an 
49 
 
observable relationship with the outcome. The variable direct ICU transfer status is a good 
example; a greater proportion of those directly transferred to the ICU at the time of 
hospitalization experienced the outcome versus those who were not transferred 
(transferred: yes = 33.7% versus no = 14.4%; not transferred: yes = 66.3% versus no = 
85.6%), but substantial percentage variation between exposure quartiles was not observed 
for either those transferred (e.g., Q1 = 16.6% versus Q4 = 16.3%) or those not transferred 
(e.g., Q1 = 83.4% versus Q4 = 84.7%). Very similar patterns were noted in Table 6 for 
PM2.5 derived observations.  
Logistic regression results for the relationship between continuous PM10 exposure 
and mortality at thirty days can be seen in Tables 7-8, reflecting minimally and partially 
adjusted models. Logistic regression results for the relationship between continuous PM2.5 
exposure and mortality at thirty days can be seen in Tables 9-10, reflecting minimally and 
partially adjusted models. As fully adjusted models differed only slightly from partially 
adjusted models with minimal change in the primary relationship of interest, the results for 
PM for the fully adjusted models were reported here and not as a full table; fully adjusted 
PM10 (per five ug/m
3increase) AOR = 1.02 (p = 0.5136, 95% CI = 0.96-1.08) and fully 
adjusted PM2.5 AOR (per five unit increase) = 1.06 (p = 0.2608, 95% CI = 0.96-1.16).  
The use of log transformed PM10 and PM2.5 variables did not result in significant 
alterations to results in any model; e.g., minimally adjusted PM10 (per one unit increase) 
AOR = 1.08 (p = 0.3980, 95% CI = 0.90-1.29) and minimally adjusted PM2.5 (per one unit 
increase) AOR = 1.14 (p = 0.2009, 95% CI = 0.93-1.38). Non-transformed exposure 
variables were reported due to ease of interpretation. 
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The minimally adjusted PM10 (continuous) logistic model revealed increased age 
at enrollment (AOR = 1.05, 95% CI = 1.04-1.05), male sex (AOR = 1.41, 95% CI = 1.18-
1.67), pneumococcal vaccine receival (AOR = 0.78, 95% CI = 0.64-0.94), and seasonal 
influenza vaccine receival (AOR = 0.82, 95% CI = 0.67-0.99) to be significantly associated 
with the outcome; PM10 (continuous) was not significantly associated. The partially 
adjusted PM10 (continuous) logistic model revealed increased age (AOR = 1.02, 95% CI = 
1.01-1.03), black race (AOR = 0.68, 95% CI = 0.52-0.89), transfer to ICU at hospitalization 
(AOR = 1.65, 95% CI = 1.33-2.06), elevated PSI (Class IV: AOR = 4.05, 95% CI = 1.44-
11.40; Class V: AOR = 11.13, 95% CI = 3.91-31.65), use of intravenous antibiotics within 
the past 90 days (AOR = 1.55, 95% CI = 1.25-1.93), suspicion of aspiration (AOR = 1.62, 
95% CI = 1.27-2.05), and pneumococcal vaccine receival (AOR = 0.76, 95% CI = 0.62-
0.93) to be associated with the outcome; PM10 (continuous) was not significantly 
associated. 
The minimally adjusted PM2.5 (continuous) logistic model revealed increased age 
at enrollment (AOR = 1.05, 95% CI = 1.04-1.05), male sex (AOR = 1.41, 95% CI = 1.18-
1.68), pneumococcal vaccine receival (AOR = 0.78, 95% CI = 0.65-0.95), and seasonal 
influenza vaccine receival (AOR = 0.81, 95% CI = 0.67-0.98) to be significantly associated 
with the outcome; PM2.5 (continuous) was significantly associated. The partially adjusted 
PM2.5 (continuous) logistic model revealed increased age (AOR = 1.02, 95% CI = 1.01-
1.03), black race (AOR = 0.68, 95% CI = 0.52-0.89), transfer to ICU at hospitalization 
(AOR = 1.65, 95% CI = 1.33-2.05), elevated PSI (Class IV: AOR = 4.06, 95% CI = 1.44-
11.42; Class V: AOR = 11.20, 95% CI = 3.94-31.84), use of intravenous antibiotics within 
the past 90 days (AOR = 1.55, 95% CI = 1.25-1.93), suspicion of aspiration (AOR = 1.61, 
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95% CI = 1.27-2.04), and pneumococcal vaccine receival (AOR = 0.76, 95% CI = 0.62-
0.93) to be associated with the outcome; PM2.5 (continuous) was not significantly 
associated.  
Table 7: Logistic regression examining association between PM10 (continuous) exposure at time of 
hospitalization and mortality at thirty days – minimally adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM10 (continuous), per 
five- ug/m3 increase 
1.02 0.4845 0.96-1.08 
Age at enrollment, per one-
year increase 
1.05 <0.0001 1.04-1.05 
Sex    
Female referent referent referent 
Male 1.41 0.0001 1.18-1.67 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.78 0.0104 0.64-0.94 
Missing 2.63 0.5282 0.13-52.86 
Seasonal influenza vaccine 
receival status 
   
No referent referent referent 
Yes 0.82 0.0382 0.67-0.99 
Missing 0.16 0.2241 0.01-3.11 














Table 8: Logistic regression examining association between PM10 (continuous) exposure at time of 
hospitalization and mortality at thirty days – partially adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM10 (continuous), per 
five- ug/m3 increase 
1.02 0.5109 0.96-1.08 
Age at enrollment, per one-
year increase 
1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.6911 0.86-1.25 
Race    
White referent  referent  referent 
Black 0.68 0.0051 0.52-0.89 
Other 0.41 0.3960 0.05-3.22 
Transfer to ICU at 
hospitalization 
   
No referent  referent  referent 
Yes 1.65 <0.0001 1.33-2.06 
PSI    
I referent  referent  referent 
II 0.64 0.4631 0.19-2.11 
III 1.50 0.4596 0.51-4.37 
IV 4.05 0.0080 1.44-11.40 
V 11.13 <0.0001 3.91-31.65 
Use of intravenous 
antibiotics within the past 
90 days 
   
No referent  referent  referent 
Yes 1.55 <0.0001 1.25-1.93 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.92 0.4411 0.74-1.14 
Current smoker 0.79 0.1006 0.60-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.62 <0.0001 1.27-2.05 
Missing <0.01 0.9799 <0.01->999.99 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.76 0.0076 0.62-0.93 
Missing 1.14 0.9289 0.07-19.08 
Seasonal influenza vaccine 
receival status 
   
No referent  referent  referent 
Yes 0.85 0.1163 0.69-1.04 
Missing 0.33 0.4441 0.02-5.51 





Table 9: Logistic regression examining association between PM2.5 (continuous) exposure at time of 
hospitalization and mortality at thirty days – minimally adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM2.5 (continuous), per 
five- ug/m3 increase 
1.05 0.2998 0.96-1.15 
Age at enrollment, per one-
year increase 
1.05 <0.0001 1.04-1.05 
Sex    
Female referent referent  referent 
Male 1.41 0.0001 1.18-1.68 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.78 0.0114 0.65-0.95 
Missing 2.70 0.5180 0.13-54.90 
Seasonal influenza vaccine 
receival status 
   
No referent referent referent 
Yes 0.81 0.0305 0.67-0.98 
Missing 0.15 0.2224 0.01-3.10 

















Table 10: Logistic regression examining association between PM2.5 (continuous) exposure at time 
of hospitalization and mortality at thirty days – partially adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM2.5 (continuous), per 
five- ug/m3 increase 
1.06 0.2577 0.96-1.16 
Age at enrollment, per one-
year increase 
1.02 <0.0001 1.01-1.03 
Race    
White referent  referent  referent 
Black 0.68 0.0051 0.52-0.89 
Other 0.41 0.3974 0.05-3.23 
Transfer to ICU at 
hospitalization 
   
No referent  referent  referent 
Yes 1.65 <0.0001 1.33-2.05 
PSI    
I referent  referent  referent 
II 0.64 0.4650 0.19-2.11 
III 1.50 0.4553 0.51-4.39 
IV 4.06 0.0079 1.44-11.42 
V 11.20 <0.0001 3.94-31.84 
Use of intravenous 
antibiotics within the past 
90 days 
   
No referent  referent  referent 
Yes 1.55 <0.0001 1.25-1.93 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.92 0.4378 0.74-1.14 
Current smoker 0.79 0.0985 0.60-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.61 <0.0001 1.27-2.04 
Missing <0.01 0.9801 <0.01->999.99 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.76 0.0081 0.62-0.93 
Missing 1.17 0.9142 0.07-19.90 
Seasonal influenza vaccine 
receival status 
   
No referent  referent  referent 
Yes 0.84 0.1005 0.69-1.03 
Missing 0.33 0.4411 0.02-5.52 
a: Adjusted odds ratio 
 
Logistic regression results for the relationship between PM10 exposure divided into 
quartiles and mortality at thirty days can be seen in Tables 11-12, reflecting minimally 
adjusted (Table 11) and partially adjusted (Table 12) models. Logistic regression results 
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for the relationship between PM2.5 exposure divided into quartiles and mortality at thirty 
days can be seen in Tables 13-14, reflecting minimally adjusted (Table 13) and partially 
adjusted (Table 14) models. As fully adjusted models differed only slightly from partially 
adjusted models with minimal change in the primary relationship of interest, the results for 
PM for the fully adjusted models are reported here and not as a full table: PM10 (quartile 
2) AOR = 1.03 (p = 0.8163, 95% CI = 0.80-1.33) and fully adjusted PM2.5 (quartile 2) AOR 
= 1.11 (p = 0.4386, 95% CI = 0.85-1.44), PM10 (quartile 3) AOR = 1.00 (p = 0.9824, 95% 
CI = 0.77-1.30) and fully adjusted PM2.5 (quartile 3) AOR = 1.20 (p = 0.1617, 95% CI = 
0.93-1.55), PM10 (quartile 4) AOR = 1.10 (p = 0.4605, 95% CI = 0.85-1.43) and fully 
adjusted PM2.5 (quartile 4) AOR = 1.17 (p = 0.2372, 95% CI = 0.90-1.52). 
The minimally adjusted PM10 (quartile) logistic model revealed increased age at 
enrollment (AOR = 1.05, 95% CI = 1.04-1.05), male sex (AOR = 1.41, 95% CI = 1.18-
1.67), pneumococcal vaccine receival (AOR = 0.78, 95% CI = 0.64-0.94), and seasonal 
influenza vaccine receival (AOR = 0.82, 95% CI = 0.67-0.99) to be significantly associated 
with the outcome; PM10 (quartile) was not significantly associated and no significant trend 
was detected. The partially adjusted PM10 (quartile) logistic model revealed increased age 
(AOR = 1.02, 95% CI = 1.01-1.03), black race (AOR = 0.68, 95% CI = 0.52-0.89), transfer 
to ICU at hospitalization (AOR = 1.66, 95% CI = 1.33-2.06), elevated PSI (Class IV: AOR 
= 4.05, 95% CI = 1.44-11.40; Class V: AOR = 11.13, 95% CI = 3.91-31.65), use of 
intravenous antibiotics within the past 90 days (AOR = 1.55, 95% CI = 1.25-1.93), 
suspicion of aspiration (AOR = 1.62, 95% CI = 1.27-2.05), and pneumococcal vaccine 
receival (AOR = 0.76, 95% CI = 0.62-0.93) to be significantly associated with the outcome; 
PM10 (quartile) was not significantly associated and no significant trend was detected. 
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The minimally adjusted PM2.5 (quartile) logistic model revealed increased age at 
enrollment (AOR = 1.05, 95% CI = 1.04-1.05), male sex (AOR = 1.41, 95% CI = 1.19-
1.68), pneumococcal vaccine receival (AOR = 0.78, 95% CI = 0.65-0.95), and seasonal 
influenza vaccine receival (AOR = 0.81, 95% CI = 0.67-0.98) to be significantly associated 
with the outcome; PM2.5 (quartile) was not significantly associated and no significant trend 
was detected. The partially adjusted PM2.5 (quartile) logistic model revealed increased age 
(AOR = 1.02, 95% CI = 1.01-1.03), black race (AOR = 0.68, 95% CI = 0.52-0.89), transfer 
to ICU at hospitalization (AOR = 1.65, 95% CI = 1.32-2.05), elevated PSI (Class IV: AOR 
= 4.10, 95% CI = 1.46-11.53; Class V: AOR = 11.30, 95% CI = 3.97-32.15), use of 
intravenous antibiotics within the past 90 days (AOR = 1.55, 95% CI = 1.24-1.92), 
suspicion of aspiration (AOR = 1.61, 95% CI = 1.27-2.05), and pneumococcal vaccine 
receival (AOR = 0.76, 95% CI = 0.62-0.93) to be significantly associated with the outcome; 





















Table 11: Logistic regression examining association between PM10 (quartile) exposure at time of 
hospitalization and mortality at thirty days – minimally adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM10 (quartile)    
1 (≤ 9.67 μg/m3) referent referent  referent 
2 (> 9.67 μg/m3 and ≤ 15.00 
μg/m3) 
1.02 0.8796 0.80-1.31 
3 (> 15.00 μg/m3 and ≤ 20.50 
μg/m3) 
1.04 0.7805 0.81-1.33 
4 (> 20.50 μg/m3) 1.11 0.3977 0.87-1.43 
p-value (trend) 0.3751 
Age at enrollment, per one-year increase 1.05 <0.0001 1.04-1.05 
Sex    
Female referent referent referent 
Male 1.41 0.0001 1.18-1.67 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.78 0.0105 0.64-0.94 
Missing 2.61 0.5316 0.13-53.03 
Seasonal influenza vaccine receival status    
No referent referent referent 
Yes 0.82 0.0394 0.67-0.99 
Missing 0.16 0.2256 0.01-3.14 
















Table 12: Logistic regression examining association between PM10 (quartile) exposure at time of 
hospitalization and mortality at thirty days – partially adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM10 (quartile)    
1 (≤ 9.67 μg/m3) referent referent  referent 
2 (> 9.67 μg/m3 and ≤ 15.00 
μg/m3) 
1.03 0.8207 0.80-1.33 
3 (> 15.00 μg/m3 and ≤ 20.50 
μg/m3) 
1.00 0.9752 0.76-1.29 
4 (> 20.50 μg/m3) 1.10 0.4604 0.85-1.43 
p-value (trend) 0.4969 
Age at enrollment, per one-year increase 1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.7099 0.86-1.25 
Race    
White referent  referent  referent 
Black 0.68 0.0051 0.52-0.89 
Other 0.41 0.3979 0.05-3.23 
Transfer to ICU at hospitalization    
No referent  referent  referent 
Yes 1.66 <0.0001 1.33-2.06 
PSI    
I referent  referent  referent 
II 0.64 0.4629 0.19-2.11 
III 1.50 0.4594 0.51-4.37 
IV 4.05 0.0080 1.44-11.40 
V 11.13 <0.0001 3.91-31.65 
Use of intravenous antibiotics within the 
past 90 days 
   
No referent  referent  referent 
Yes 1.55 <0.0001 1.25-1.93 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.92 0.4411 0.74-1.14 
Current smoker 0.79 0.0996 0.60-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.62 <0.0001 1.27-2.05 
Missing <0.01 0.9799 <0.01->999.99 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.76 0.0077 0.62-0.93 
Missing 1.13 0.9308 0.07-19.02 
Seasonal influenza vaccine receival status    
No referent  referent  referent 
Yes 0.85 0.1141 0.69-1.04 
Missing 0.34 0.4453 0.02-5.53 





Table 13: Logistic regression examining association between PM2.5 (quartile) exposure at time of 
hospitalization and mortality at thirty days – minimally adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM2.5 (quartile)    
1 (≤ 7.07 μg/m3) referent referent  referent 
2 (> 7.07 μg/m3 and ≤ 9.63 
μg/m3) 
1.10 0.4631 0.85-1.41 
3 (> 9.63 μg/m3 and ≤ 13.37 
μg/m3) 
1.21 0.1270 0.95-1.55 
4 (> 13.37 μg/m3) 1.15 0.2700 0.90-1.48 
p-value (trend)  0.2642 
Age at enrollment, per one-year increase 1.05 <0.0001 1.04-1.05 
Sex    
Female referent referent  referent 
Male 1.41 0.0001 1.19-1.68 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.78 0.0113 0.65-0.95 
Missing 2.74 0.5156 0.13-56.86 
Seasonal influenza vaccine receival 
status 
   
No referent referent referent 
Yes 0.81 0.0316 0.67-0.98 
Missing 0.15 0.2227 0.01-3.13 















Table 14: Logistic regression examining association between PM2.5 (quartile) exposure at time of 
hospitalization and mortality at thirty days – partially adjusted (N = 6145, events = 597) 
Variable AORa p-value CI (95%) 
PM2.5 (quartile)    
1 (≤ 7.07 μg/m3) referent referent  referent 
2 (> 7.07 μg/m3 and ≤ 9.63 
μg/m3) 
1.11 0.4347 0.85-1.44 
3 (> 9.63 μg/m3 and ≤ 13.37 
μg/m3) 
1.20 0.1606 0.93-1.55 
4 (> 13.37 μg/m3) 1.17 0.2334 0.90-1.52 
p-value (trend) 0.2390 
Age at enrollment, per one-year increase 1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.6746 0.86-1.25 
Race    
White referent  referent  referent 
Black 0.68 0.0050 0.52-0.89 
Other 0.41 0.3928 0.05-3.21 
Transfer to ICU at hospitalization    
No referent  referent  referent 
Yes 1.65 <0.0001 1.32-2.05 
PSI    
I referent  referent  referent 
II 0.65 0.4726 0.20-2.13 
III 1.52 0.4460 0.52-4.42 
IV 4.10 0.0075 1.46-11.53 
V 11.30 <0.0001 3.97-32.15 
Use of intravenous antibiotics within the 
past 90 days 
   
No referent  referent  referent 
Yes 1.55 <0.0001 1.24-1.92 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.92 0.4526 0.74-1.14 
Current smoker 0.80 0.1061 0.61-1.05 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.61 <0.0001 1.27-2.05 
Missing <0.01 0.9800 <0.01->999.99 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.76 0.0082 0.62-0.93 
Missing 1.17 0.9121 0.07-20.41 
Seasonal influenza vaccine receival status    
No referent  referent  referent 
Yes 0.84 0.1000 0.69-1.03 
Missing 0.33 0.4428 0.02-5.61 




Cox proportional hazards regression results for the relationship between continuous 
PM10 exposure and mortality at thirty days can be seen in Tables 15-16, reflecting 
minimally adjusted (Table 15) and partially adjusted (Table 16) models. Cox proportional 
hazards regression results for the relationship between continuous PM2.5 exposure and 
mortality at thirty days can be seen in Tables 17-18, reflecting minimally adjusted (Table 
17) and partially adjusted (Table 18) models. As fully adjusted models differed only 
slightly from partially adjusted models with minimal change in the primary relationship of 
interest, the results for PM for the fully adjusted models were reported here and not as a 
full table: fully adjusted PM10 (per five unit increase) AHR = 1.02 (p = 0.4831, 95% CI = 
0.97-1.07) and fully adjusted PM2.5 (per five unit increase) AHR = 1.05 (p = 0.2473, 95% 
CI = 0.97-1.14). Total survival time, in person days, was 173,814 person days. 
The use of log transformed PM10 and PM2.5 variables did not result in significant 
alterations to results in any model; e.g., minimally adjusted PM10 (per one unit increase) 
AHR =  1.07 (p = 0.3856, 95% CI = 0.91-1.27) and minimally adjusted PM2.5 (per one unit 
increase) AHR = 1.13 (p = 0.1986, 95% CI = 0.94-1.35). Non-transformed exposure 
variables were reported due to ease of interpretation. 
The minimally adjusted PM10 (continuous) Cox proportional hazards model 
revealed increased age at enrollment (AOR = 1.04, 95% CI = 1.04-1.05), male sex (AOR 
= 1.38, 95% CI = 1.17-1.62), pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.67-
0.95), and seasonal influenza vaccine receival (AOR = 0.82, 95% CI = 0.69-0.99) to be 
significantly associated with the outcome; PM10 (continuous) was not significantly 
associated. The partially adjusted PM10 (continuous) Cox proportional hazards model 
revealed increased age (AOR = 1.02, 95% CI = 1.01-1.03), black race (AOR = 0.69, 95% 
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CI = 0.54-0.88), transfer to ICU at hospitalization (AOR = 1.59, 95% CI = 1.32-1.93), 
elevated PSI (Class IV: AOR = 4.05, 95% CI = 1.46-11.24; Class V: AOR = 10.19, 95% 
CI = 3.64-28.53), use of intravenous antibiotics within the past 90 days (AOR = 1.45, 95% 
CI = 1.20-1.75), suspicion of aspiration (AOR = 1.49, 95% CI = 1.22-1.83), and 
pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.66-0.94) to be significantly 
associated with the outcome; PM10 (continuous) was not significantly associated. 
The minimally adjusted PM2.5 (continuous) Cox proportional hazards model 
revealed increased age at enrollment (AOR = 1.04, 95% CI = 1.04-1.05), male sex (AOR 
= 1.38, 95% CI = 1.17-1.62), pneumococcal vaccine receival (AOR = 0.80, 95% CI = 0.67-
0.95), and seasonal influenza vaccine receival (AOR = 0.82, 95% CI = 0.67-0.98) to be 
significantly associated with the outcome; PM2.5 (continuous) was not significantly 
associated. The partially adjusted PM2.5 (continuous) Cox proportional hazards model 
revealed increased age (AOR = 1.02, 95% CI = 1.01-1.03), black race (AOR = 0.69, 95% 
CI = 0.54-0.88), transfer to ICU at hospitalization (AOR = 1.59, 95% CI = 1.32-1.92), 
elevated PSI (Class IV: AOR = 4.06, 95% CI = 1.46-11.26; Class V: AOR = 10.24, 95% 
CI = 3.66-28.67), use of intravenous antibiotics within the past 90 days (AOR = 1.45, 95% 
CI = 1.20-1.75), suspicion of aspiration (AOR = 1.49, 95% CI = 1.21-1.82), and 
pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.66-0.94) to be significantly 









Table 15: Cox proportional hazards regression examining association between PM10 (continuous) 
exposure at time of hospitalization and mortality at thirty days – minimally adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM10 (continuous), per 
five- ug/m3 increase 
1.02 0.4719 0.97-1.07 
Age at enrollment, per one-
year increase 
1.04 <0.0001 1.04-1.05 
Sex    
Female referent referent referent 
Male 1.38 0.0001 1.17-1.62 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.79 0.0103 0.67-0.95 
Missing 2.34 0.5279 0.17-32.78 
Seasonal influenza vaccine 
receival status 
   
No referent referent referent 
Yes 0.82 0.0347 0.69-0.99 
Missing 0.18 0.2103 0.01-2.59 
















Table 16: Cox proportional hazards regression examining association between PM10 (continuous) 
exposure at time of hospitalization and mortality at thirty days – partially adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM10 (continuous), per 
five- ug/m3 increase 
1.02 0.4796 0.97-1.07 
Age at enrollment, per one-
year increase 
1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.6570 0.88-1.23 
Race    
White referent  referent  referent 
Black 0.69 0.0033 0.54-0.88 
Other 0.43 0.4007 0.06-3.07 
Transfer to ICU at 
hospitalization 
   
No referent  referent  referent 
Yes 1.59 <0.0001 1.32-1.93 
PSI    
I referent  referent  referent 
II 0.65 0.4794 0.20-2.13 
III 1.53 0.4292 0.53-4.42 
IV 4.05 0.0073 1.46-11.24 
V 10.19 <0.0001 3.64-28.53 
Use of intravenous 
antibiotics within the past 
90 days 
   
No referent  referent  referent 
Yes 1.45 0.0001 1.20-1.75 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.93 0.4366 0.77-1.12 
Current smoker 0.81 0.1049 0.64-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.49 0.0001 1.22-1.83 
Missing 0.00 0.9693 0.00-0.00 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.79 0.0090 0.66-0.94 
Missing 1.06 0.9607 0.10-11.60 
Seasonal influenza vaccine 
receival status 
   
No referent  referent  referent 
Yes 0.86 0.1047 0.72-1.03 
Missing 0.39 0.4379 0.03-4.24 





Table 17: Cox proportional hazards regression examining association between PM2.5 (continuous) 
exposure at time of hospitalization and mortality at thirty days – minimally adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM2.5 (continuous), per 
five- ug/m3 increase 
1.05 0.2959 0.96-1.14 
Age at enrollment, per one-
year increase 
1.04 <0.0001 1.04-1.05 
Sex    
Female referent referent  referent 
Male 1.38 <0.0001 1.17-1.62 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.80 0.0114 0.67-0.95 
Missing 2.40 0.5167 0.17-34.06 
Seasonal influenza vaccine 
receival status 
   
No referent referent referent 
Yes 0.82 0.0278 0.67-0.98 
Missing 0.18 0.2087 0.01-2.59 
















Table 18: Cox proportional hazards regression examining association between PM2.5 (continuous) 
exposure at time of hospitalization and mortality at thirty days – partially adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM2.5 (continuous), per 
five- ug/m3 increase 
1.05 0.2436 0.97-1.14 
Age at enrollment, per one-
year increase 
1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.6366 0.88-1.23 
Race    
White referent  referent  referent 
Black 0.69 0.0033 0.54-0.88 
Other 0.43 0.4018 0.06-3.08 
Transfer to ICU at 
hospitalization 
   
No referent  referent  referent 
Yes 1.59 <0.0001 1.32-1.92 
PSI    
I referent  referent  referent 
II 0.65 0.4813 0.20-2.14 
III 1.54 0.4253 0.53-4.44 
IV 4.06 0.0072 1.46-11.26 
V 10.24 <0.0001 3.66-28.67 
Use of intravenous 
antibiotics within the past 
90 days 
   
No referent  referent  referent 
Yes 1.45 0.0001 1.20-1.75 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.93 0.4354 0.77-1.12 
Current smoker 0.81 0.1009 0.63-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.49 0.0001 1.21-1.82 
Missing 0.00 0.9695 0.00-0.00 
Pneumococcal vaccine 
receival status 
   
No referent referent referent 
Yes 0.79 0.0098 0.66-0.94 
Missing 1.09 0.9437 0.10-12.12 
Seasonal influenza vaccine 
receival status 
   
No referent  referent  referent 
Yes 0.86 0.0895 0.72-1.02 
Missing 0.38 0.4349 0.03-4.26 




Cox proportional hazards regression results for the relationship between PM10 
exposure divided into quartiles and mortality at thirty days can be seen in Tables 19-20, 
reflecting minimally adjusted (Table 19) and partially adjusted (Table 20) models. Cox 
proportional hazards regression results for the relationship between PM2.5 exposure divided 
into quartiles and mortality at thirty days can be seen in Tables 21-22, reflecting minimally 
adjusted (Table 21) and partially adjusted (Table 22) models. As fully adjusted models 
differed only slightly from partially adjusted models with minimal change in the primary 
relationship of interest, the results for PM for the fully adjusted models were reported here 
and not as a full table: PM10 (quartile 2) AHR = 1.04 (p = 0.7620, 95% CI = 0.82-1.30) and 
fully adjusted PM2.5 (quartile 2) AHR = 1.13 (p = 0.3088, 95% CI = 0.89-1.43), PM10 
(quartile 3) AHR = 0.99 (p = 0.9099, 95% CI = 0.78-1.25) and fully adjusted PM2.5 (quartile 
3) AHR = 1.17 (p = 0.1817, 95% CI = 0.93-1.47), PM10 (quartile 4) AHR = 1.10 (p = 
0.4062, 95% CI = 0.88-1.39) and fully adjusted PM2.5 (quartile 4) AHR = 1.17 (p = 0.1906, 
95% CI = 0.93-1.47). Total survival time, in person days, was 173,814 person/days. 
The minimally adjusted PM10 (quartile) Cox proportional hazards model revealed 
increased age at enrollment (AOR = 1.04, 95% CI = 1.04-1.05), male sex (AOR = 1.37, 
95% CI = 1.17-1.61), pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.67-0.95), 
and seasonal influenza vaccine receival (AOR = 0.83, 95% CI = 0.69-0.99) to be 
significantly associated with the outcome; PM10 (quartile) was not significantly associated 
and no significant trend was detected. The partially adjusted PM10 (quartile) Cox 
proportional hazards model revealed increased age (AOR = 1.02, 95% CI = 1.01-1.03), 
black race (AOR = 0.69, 95% CI = 0.54-0.88), transfer to ICU at hospitalization (AOR = 
1.60, 95% CI = 1.32-1.93), elevated PSI (Class IV: AOR = 4.04, 95% CI = 1.45-11.22; 
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Class V: AOR = 10.17, 95% CI = 3.63-28.47), use of intravenous antibiotics within the 
past 90 days (AOR = 1.45, 95% CI = 1.20-1.75), suspicion of aspiration (AOR = 1.49, 95% 
CI = 1.22-1.83), and pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.66-0.94) to 
be significantly associated with the outcome; PM10 (quartile) was not significantly 
associated and no significant trend was detected. 
The minimally adjusted PM2.5 (quartile) Cox proportional hazards model revealed 
increased age at enrollment (AOR = 1.04, 95% CI = 1.04-1.05), male sex (AOR = 1.38, 
95% CI = 1.17-1.62), pneumococcal vaccine receival (AOR = 0.80, 95% CI = 0.67-0.95), 
and seasonal influenza vaccine receival (AOR = 0.82, 95% CI = 0.69-0.98) to be 
significantly associated with the outcome; PM2.5 (quartile) was not significantly associated 
and no significant trend was detected. The partially adjusted PM2.5 (quartile) Cox 
proportional hazards model revealed increased age (AOR = 1.02, 95% CI = 1.01-1.03), 
black race (AOR = 0.69, 95% CI = 0.54-0.88), transfer to ICU at hospitalization (AOR = 
1.59, 95% CI = 1.31-1.92), elevated PSI (Class IV: AOR = 4.10, 95% CI = 1.48-11.38; 
Class V: AOR = 10.34, 95% CI = 3.69-28.96), use of intravenous antibiotics within the 
past 90 days (AOR = 1.45, 95% CI = 1.20-1.75), suspicion of aspiration (AOR = 1.49, 95% 
CI = 1.21-1.82), and pneumococcal vaccine receival (AOR = 0.79, 95% CI = 0.66-0.94) to 
be significantly associated with the outcome; PM2.5 (quartile) was not significantly 









Table 19: Cox proportional hazards regression examining association between PM10 (quartile) 
exposure at time of hospitalization and mortality at thirty days – minimally adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM10 (quartile)    
1 (≤ 9.67 μg/m3) referent referent  referent 
2 (> 9.67 μg/m3 and ≤ 15.00 
μg/m3) 
1.02 0.8795 0.81-1.28 
3 (> 15.00 μg/m3 and ≤ 20.50 
μg/m3) 
1.03 0.8071 0.81-1.30 
4 (> 20.50 μg/m3) 1.11 0.3765 0.88-1.40 
p-value (trend) 0.3562 
Age at enrollment, per one-year increase 1.04 <0.0001 1.04-1.05 
Sex    
Female referent referent referent 
Male 1.37 0.0001 1.17-1.61 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.79 0.0104 0.67-0.95 
Missing 2.33 0.5315 0.16-32.96 
Seasonal influenza vaccine receival status    
No referent referent referent 
Yes 0.83 0.0357 0.69-0.99 
Missing 0.18 0.2119 0.01-2.62 















Table 20: Cox proportional hazards regression examining association between PM10 (quartile) 
exposure at time of hospitalization and mortality at thirty days – partially adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM10 (quartile)    
1 (≤ 9.67 μg/m3) referent referent  referent 
2 (> 9.67 μg/m3 and ≤ 15.00 
μg/m3) 
1.04 0.7657 0.82-1.30 
3 (> 15.00 μg/m3 and ≤ 20.50 
μg/m3) 
0.99 0.9035 0.78-1.25 
4 (> 20.50 μg/m3) 1.10 0.4049 0.88-1.40 
p-value (trend) 0.4646 
Age at enrollment, per one-year increase 1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.03 0.6934 0.88-1.22 
Race    
White referent  referent  referent 
Black 0.69 0.0033 0.54-0.88 
Other 0.43 0.4042 0.06-3.09 
Transfer to ICU at hospitalization    
No referent  referent  referent 
Yes 1.60 <0.0001 1.32-1.93 
PSI    
I referent  referent  referent 
II 0.65 0.4479 0.20-2.13 
III 1.53 0.4306 0.53-4.42 
IV 4.04 0.0074 1.45-11.22 
V 10.17 <0.0001 3.63-28.47 
Use of intravenous antibiotics within the 
past 90 days 
   
No referent  referent  referent 
Yes 1.45 0.0001 1.20-1.75 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.93 0.4349 0.77-1.12 
Current smoker 0.81 0.1034 0.64-1.04 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.49 <0.0001 1.22-1.83 
Missing 0.00 0.9691 0.00-0.00 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.79 0.0096 0.66-0.94 
Missing 1.06 0.9621 0.10-11.58 
Seasonal influenza vaccine receival status    
No referent  referent  referent 
Yes 0.86 0.1009 0.72-1.03 
Missing 0.39 0.4385 0.04-4.25 




Table 21: Cox proportional hazards regression examining association between PM2.5 (quartile) 
exposure at time of hospitalization and mortality at thirty days – minimally adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM2.5 (quartile)    
1 (≤ 7.07 μg/m3) referent referent  referent 
2 (> 7.07 μg/m3 and ≤ 9.63 
μg/m3) 
1.10 0.4159 0.87-1.39 
3 (> 9.63 μg/m3 and ≤ 13.37 
μg/m3) 
1.19 0.1304 0.95-1.50 
4 (> 13.37 μg/m3) 1.14 0.2546 0.91-1.44 
p-value (trend) 0.2615 
Age at enrollment, per one-year increase 1.04 <0.0001 1.04-1.05 
Sex    
Female referent referent  referent 
Male 1.38 <0.0001 1.17-1.62 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.80 0.0111 0.67-0.95 
Missing 2.44 0.5136 0.17-35.55 
Seasonal influenza vaccine receival status    
No referent referent referent 
Yes 0.82 0.0288 0.69-0.98 
Missing 0.18 0.2098 0.01-2.62 















Table 22: Cox proportional hazards regression examining association between PM2.5 (quartile) 
exposure at time of hospitalization and mortality at thirty days – partially adjusted (N = 6145, 
events = 597, person/days = 173814) 
Variable AHRa p-value CI (95%) 
PM2.5 (quartile)    
1 (≤ 7.07 μg/m3) referent referent  referent 
2 (> 7.07 μg/m3 and ≤ 9.63 
μg/m3) 
1.13 0.3056 0.89-1.43 
3 (> 9.63 μg/m3 and ≤ 13.37 
μg/m3) 
1.17 0.1798 0.93-1.47 
4 (> 13.37 μg/m3) 1.17 0.1870 0.93-1.48 
p-value (trend) 0.2242 
Age at enrollment, per one-year increase 1.02 <0.0001 1.01-1.03 
Sex    
Female referent referent  referent 
Male 1.04 0.6353 0.88-1.23 
Race    
White referent  referent  referent 
Black 0.69 0.0032 0.54-0.88 
Other 0.42 0.3934 0.06-3.03 
Transfer to ICU at hospitalization    
No referent  referent  referent 
Yes 1.59 <0.0001 1.31-1.92 
PSI    
I referent  referent  referent 
II 0.66 0.4886 0.20-2.15 
III 1.55 0.4160 0.54-4.48 
IV 4.10 0.0068 1.48-11.38 
V 10.34 <0.0001 3.69-28.96 
Use of intravenous antibiotics within the 
past 90 days 
   
No referent  referent  referent 
Yes 1.45 0.0001 1.20-1.75 
Smoking status    
Non-smoker referent  referent  referent 
Past smoker 0.93 0.4515 0.77-1.12 
Current smoker 0.82 0.1123 0.64-1.05 
Suspicion of aspiration    
No referent  referent  referent 
Yes 1.49 0.0001 1.22-1.82 
Missing 0.00 0.9694 0.00-0.00 
Pneumococcal vaccine receival status    
No referent referent referent 
Yes 0.79 0.0098 0.66-0.94 
Missing 1.10 0.9379 0.10-12.65 
Seasonal influenza vaccine receival status    
No referent  referent  referent 
Yes 0.86 0.0910 0.72-1.02 
Missing 0.38 0.4373 0.03-4.36 





 Due to the presence of only two monitoring stations providing PM10 values within 
the study area and during the study timeframe, kriging could not be conducted. ArcMap 
was unable to conduct the interpolation given the sparsity of data available, despite 
attempting to use different methods to complete the kriging process. Two data points was 
simply too small a sample size. 
 Monitoring stations providing PM2.5 values varied from two to four in number, 
depending on the day, though three appeared to be the most common; the Durrett Lane 
monitoring station provided data approximately every three days, versus approximately 
daily for the other monitoring stations. On days where only two monitoring stations 
provided data, ArcGIS was unable to conduct the interpolation; this was for the same 
reason previously noted for the PM10 data. On almost every day where models were able 
to be created, the models produced seemed to not accurately represent localized PM-related 
fluctuations, but rather broad patterns of distribution based on the directional increase, 
decrease, or plateauing of PM2.5 values (Figures 7 and 8). Rarely, models (Figure 9) were 
created that seemed to account for some degree of local variation, but given the sparsity of 
point data available, the accuracy of such models is questionable. Such observations did 
not seem to vary depending on the time of year examined. Examples are provided. 
 The example models are each problematic in their own ways. Figure 7 indicates an 
east-to-west pattern of gradually increasing PM2.5 concentration, but the basis of the pattern 
is simply that the three included monitors for the given day happened to be spatially located 
from east to west and reported corresponding low-to-high concentration values. The 
monitors are located within mid, west, and southwest Louisville, and likely fail to 
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accurately represent localized concentration variations in other portions of the county. 
Determining such a broad pattern for the relatively large Jefferson county study area based 
upon such a limited source of data is potentially misleading. A similar issue to that of 
Figure 7 manifested in Figure 8. The monitors for the given day all presented similar PM2.5 
measurements, which was ultimately interpreted as the entire county having roughly the 
same level of exposure. Again, given the large size of the study area and only three 
monitors providing localized data for the given day, it seems misleading to assume the 
entire county had the same level of exposure based on the available data. Figure 9 did 
portray a semblance of the localized patterns that should be portrayed when kriging is 
successfully implemented, which was a minor success. However, given the issues seen in 
models constructed based upon three monitors, there is the possibility that these patterns 
are not entirely accurate, as the addition of data from a fourth monitor in much the same 












Figure 8 - Example of homogenous pattern resulting from similar values across three point sources 
 
 





Effect Modification in Spatially Averaged Data – PM10 
 We examined effect modification by continuous age, sex, and race on the 
relationship between PM10 (continuous) exposure and mortality at 30 days and did not 
observe statistically significant interactions by PM10 and age, or sex, but did observe 
statistically significant interaction between PM10 and race. Analysis of effect modification 
by continuous age on the relationship between PM10 (continuous) exposure and mortality 
at 30 days yielded a Wald (one additional degree of freedom) p-value of 0.5324. Adjusted 
odds ratio from the partially adjusted logistic regression model with interaction term 
included was 1.01 (95% CI = 0.94-1.08) per five-unit PM10 increase. Analysis of effect 
modification by sex on the relationship between PM10 (continuous) exposure and mortality 
at 30 days yielded a Wald (one additional degree of freedom) p-value of 0.2135. Adjusted 
odds ratios from the partially adjusted logistic regression model with interaction term 
included were as follows: female = 1.06 (95% CI = 0.97-1.15) per five-unit PM10 increase, 
male = 0.98 (95% CI = 0.91-1.07) per five-unit PM10 increase. Analysis of effect 
modification by race on the relationship between PM10 (continuous) exposure and mortality 
at 30 days yielded an LRT p-value of 0.0499. Adjusted odds ratios from the partially 
adjusted logistic regression model with interaction term included were as follows: black = 
1.19 (95% CI = 1.04-1.37) per five-unit PM10 increase, white = 0.99 (95% CI = 0.93-1.05) 
per five-unit PM10 increase, other = 1.27 (95% CI = 0.31-5.22) per five-unit PM10 increase; 
the results indicate that for every five μg/m3 increase in PM10 exposure, the odds of 
experiencing the outcome increased by 19% among black participants. 
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 Regarding models containing quartile-based exposures, adjusted (partial model) 
odds ratios for the potential effect modifiers of interest can be viewed in Tables 23-25 
along with likelihood ratio test (LRT) p-values. It should be noted that due to the small 
number of individuals falling into the race category of “other,” the results were minimally 
useful for that particular category and underpowered in the analysis of the relationship 
between PM10 (quartile) and mortality at 30 days, and were therefore excluded from effect 
modification analysis under these conditions. 
 We examined effect modification by continuous and categorical age, sex, and race 
on the relationship between PM10 (quartile) exposure and mortality at 30 days and did not 
observe statistically significant interactions by PM10 and sex, but did observe statistically 
significant interaction between PM10 and continuous and categorical age, and race. 
Analysis of effect modification by continuous age on the relationship between PM10 
quartiles and mortality at 30 days yielded an LRT p-value of 0.0013. Adjusted odds ratios 
from the partially adjusted logistic regression model with interaction term included were 
as follows: quartile 1 = referent, quartile 2 = 0.77 (95% CI = 0.56-1.05), quartile 3 = 0.97 
(95% CI = 0.73-1.29), quartile 4 = 0.92 (95% CI = 0.68-1.24). Analysis of effect 
modification by categorical age on the relationship between PM10 quartiles and mortality 
at 30 days yielded an LRT p-value of 0.0088. Adjusted odds ratios from the partially 
adjusted logistic regression model with interaction term included were as follows: <65 
years (Q1) = referent, <65 years (Q2) = 0.48 (95% CI = 0.27-0.85), <65 years (Q3) = 0.86 
(95% CI = 0.52-1.40), <65 years (Q4) = 0.67 (95% CI = 0.40-1.12), 65+ years (Q1) = 
referent, 65+ years (Q2) = 1.28 (95% CI = 0.95-1.72), 65+ years (Q3) = 1.05 (95% CI = 
0.77-1.43), 65+ years (Q4) = 1.30 (95% CI = 0.96-1.76). Analysis of effect modification 
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by sex on the relationship between PM10 quartiles and mortality at 30 days yielded an LRT 
p-value of 0.1059. Adjusted odds ratios from the partially adjusted logistic regression 
model with interaction term included were as follows: male (Q1) = referent, male (Q2) = 
0.91 (95% CI = 0.64-1.30), male (Q3) = 1.02 (95% CI = 0.71-1.46), male (Q4) = 0.86 (95% 
CI = 0.60-1.23), female (Q1) = referent, female (Q2) = 1.18 (95% CI = 0.81-1.73), female 
(Q3) = 0.98 (95% CI = 0.67-1.45), female (Q4) = 1.46 (95% CI = 1.01-2.14); the results 
indicate that female participants who fell within the fourth PM10 exposure quartile had 46% 
increased odds of experiencing the outcome. Analysis of effect modification by race on the 
relationship between PM10 quartiles and mortality at 30 days yielded an LRT p-value of 
0.0171. Adjusted odds ratios from the partially adjusted logistic regression model with 
interaction term included were as follows: white (Q1) = referent, white (Q2) = 1.01 (95% 
CI = 0.76-1.32), white (Q3) = 0.89 (95% CI = 0.67-1.18), white (Q4) = 0.96 (95% CI = 
0.72-1.26), black (Q1) = referent, black (Q2) = 1.18 (95% CI = 0.53-2.61), black (Q3) = 
2.01 (95% CI = 0.95-4.27), black (Q4) = 2.70 (95% CI = 1.31-5.55); the results indicate 
that black participants who fell within the fourth PM10 exposure quartile had 170% 
increased odds of experiencing the outcome. 
 Given the large and significant association observed among black participants in 
Q4, further analysis of the relationship was conducted, based solely upon data from each 
racially stratified participant group. Relative risk was examined, calculated as the risk of 
outcome occurrence within the exposure group, which was being within the highest 
exposure quartile, divided by the risk of outcome occurrence within the remaining groups. 
Relative risk was found to be 1.51 (95% CI = 0.95-2.39) for black participants. Individual 
risks for outcome occurrence for each quartile in the black participant group were as 
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follows: Q1 = 4.1%, Q2 = 4.8%, Q3 = 7.0%, Q4 = 7.9%. Relative risk was found to be 
1.04 (95% CI = 0.86-1.25) for white participants. Individual risks for outcome occurrence 
for each quartile in the white participant group were as follows: Q1 = 10.6%, Q2 = 11.1%, 
Q3 = 10.1%, Q4 = 11.0%. In total, those black participants in the highest exposure quartile 
did seem to maintain an elevated association with the outcome compared to those in other 
exposure quartiles, but the association was only of borderline significance. Though white 
participants had individual risks for each exposure quartile that surpassed those of black 
participants in corresponding exposure quartiles, relative risk for the white participants in 
the highest exposure quartile was low and not significant. 
Additionally, though individual comorbidity data was not utilized in this study, the 
variable PSI was assumed to serve as a summary of various factors – comorbidities among 
them. PSI participant percentages for each PSI class were compared for black and white 
participants. The percentage of black participants who fell into each PSI class was as 
follows: Class I = 9.83%, Class II = 20.31%, Class III = 19.74%, Class IV = 30.70%, and 
Class V = 19.42%. The percentage of white participants who fell into each PSI class was 
as follows: Class I = 5.48%, Class II = 15.29%, Class III = 18.51%, Class IV = 36.86%, 
and Class V = 23.85%. Based upon observations from this data, fewer black participants 
fell within the upper two PSI classes than white participants. It is possible this suggests that 
overall pneumonia mortality risk factors were not as great among black participants. Even 
among those black and white participants in the highest exposure quartile, a similar pattern 
was noted. The percentage of Q4 black participants who fell into each PSI class was as 
follows: Class I = 10.67%, Class II = 19.21%, Class III = 21.95%, Class IV = 32.32%, and 
Class V = 15.85%. The percentage of Q4 white participants who fell into each PSI class 
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was as follows: Class I = 6.22%, Class II = 14.11%, Class III = 17.84%, Class IV = 36.76%, 
and Class V = 25.06%. 
 
Table 23: Effect modification by age (category) on the relationship between PM10 (quartile) exposure and 
mortality at 30 days – partially adjusted logistic regression modela with interaction term (N = 6145, events 
= 597) 
 Adjusted Odds Ratios by Category  
PM10 Quantile  
< 65 years (95% CI) 
n = 2712 
65+ years (95% CI) 
n = 3433 
LRT p-value 
1 (≤ 9.67 μg/m3) referent 
n = 658 
x̅b = 7.45 
referent 
n = 832 





2 (> 9.67 μg/m3 and ≤ 15.00 μg/m3) 0.48 (0.27-0.85) 
n = 653 
x̅b = 12.37 
1.28 (0.95-1.72) 
n = 937 
x̅b = 12.32 
3 (> 15.00 μg/m3 and ≤ 20.50 μg/m3) 0.86 (0.52-1.40) 
n = 693 
x̅b = 17.73 
1.05 (0.77-1.43) 
n = 834 
x̅b = 17.67 
4 (> 20.50 μg/m3) 0.67 (0.40-1.12) 
n = 708 
x̅b = 27.00 
1.30 (0.96-1.76) 
n = 830 
x̅b = 26.91 
a = Adjusting for age at enrollment (continuous), age at enrollment (categorical), sex, receival of pneumococcal vaccine, 
receival of seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy within the 
past 90 days, smoking history, and suspicion of aspiration 
b = Mean PM10 (continuous) for exposure / covariate category 
 
Table 24: Effect modification by sex on the relationship between PM10 
(quartile) exposure and mortality at 30 days – partially adjusted logistic regression 
modela with interaction term (N = 6145, events = 597) 
  Adjusted Odds Ratios by Category  
PM10 Quantile  
Male (95% CI) 
n = 2857 
Female (95% CI) 
n = 3288 
LRT p-value 
1 (≤ 9.67 μg/m3) referent 
n = 683 
x̅b = 7.45 
referent 
n = 807 





2 (> 9.67 μg/m3 and ≤ 15.00 μg/m3) 0.91 (0.64-1.30) 
n = 731 
x̅b = 12.33 
1.18 (0.81-1.73) 
n = 859 
x̅b = 12.35 
3 (> 15.00 μg/m3 and ≤ 20.50 μg/m3) 1.02 (0.71-1.46) 
n = 696 
x̅b = 17.74 
0.98 (0.67-1.45) 
n = 831 
x̅b = 17.66 
4 (> 20.50 μg/m3) 0.86 (0.60-1.23) 
n = 747 
x̅b = 27.00 
1.46 (1.01-2.14) 
n = 791 
x̅b = 26.90 
a = Adjusting for age at enrollment (continuous), sex, receival of pneumococcal vaccine, receival of 
seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy 
within the past 90 days, smoking history, and suspicion of aspiration 




Table 25: Effect modification by race on the relationship between PM10 
(quartile) exposure and mortality at 30 days – partially adjusted logistic regression 
modela with interaction term (N = 6113, events = 596) 
  Adjusted Odds Ratios by Category  
PM10 Quantile  
White (95% CI) 
n = 4872 
Black (95% CI) 
n = 1241  
LRT p-value 
1 (≤ 9.67 μg/m3) referent 
n = 1164 
x̅b = 7.47 
referent 
n = 317 





2 (> 9.67 μg/m3 and ≤ 15.00 μg/m3) 1.01 (0.76-1.32) 
n = 1269 
x̅b = 12.34 
1.18 (0.53-2.61) 
n = 312 
x̅b = 12.37 
3 (> 15.00 μg/m3 and ≤ 20.50 μg/m3) 0.89 (0.67-1.18) 
n = 1234 
x̅b = 17.57 
2.01 (0.95-4.27) 
n = 284 
x̅b = 17.85 
4 (> 20.50 μg/m3) 0.96 (0.72-1.26) 
n = 1205 
x̅b = 26.94 
2.70 (1.31-5.55) 
n = 328 
x̅b = 27.01 
a = Adjusting for age at enrollment (continuous), sex, receival of pneumococcal vaccine, receival of 
seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy 
within the past 90 days, smoking history, and suspicion of aspiration 
b = Mean PM10 (continuous) for exposure / covariate category 
 
Effect Modification in Spatially Averaged Data – PM2.5 
We examined effect modification by continuous age, sex, and race on the 
relationship between PM2.5 (continuous) exposure and mortality at 30 days and did not 
observe statistically significant interactions by PM2.5 and age, sex, or race. Analysis of 
effect modification by continuous age on the relationship between PM2.5 (continuous) 
exposure and mortality at 30 days yielded a Wald (one additional degree of freedom) p-
value of 0.4933. Adjusted odds ratio from the partially adjusted logistic regression model 
with interaction term included was 1.04 (95% CI = 0.93-1.16) per five-unit PM2.5 increase. 
Analysis of effect modification by sex on the relationship between PM2.5 (continuous) 
exposure and mortality at 30 days yielded a Wald (one additional degree of freedom) p-
value of 0.6974. Adjusted odds ratios from the partially adjusted logistic regression model 
with interaction term included were as follows: female = 1.07 (95% CI = 0.93-1.23) per 
five-unit PM2.5 increase, male = 1.04 (95% CI = 0.92-1.19) per five-unit PM2.5 increase. 
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Analysis of effect modification by race on the relationship between PM2.5 (continuous) 
exposure and mortality at 30 days yielded an LRT p-value of 0.6102. Adjusted odds ratios 
from the partially adjusted logistic regression model with interaction term included were 
as follows: black = 1.18 (95% CI = 0.91-1.53) per five-unit PM2.5 increase, white = 1.04 
(95% CI = 0.94-1.15) per five-unit PM2.5 increase, other = 0.51 (95% CI = 0.01-39.90) per 
five-unit PM2.5 increase. 
Regarding models containing quartile-based exposures, adjusted (partial model) 
odds ratios for the potential effect modifiers of interest can be viewed in Tables 26-28 
along with log ratio test (LRT) p-value. It should be noted that due to the small number of 
individuals falling into the race category of “other,” the results are minimally useful for 
that particular category and underpowered in the analysis of the relationship between PM2.5 
(quartile) and mortality at 30 days, making it necessary to exclude this category from effect 
modification analysis under these conditions. 
 We examined effect modification by continuous and categorical age, sex, and race 
on the relationship between PM2.5 (quartile) exposure and mortality at 30 days and did not 
observe statistically significant interactions by PM2.5 and continuous age, sex, or race, but 
did observe statistically significant interaction between PM2.5 and categorical age. Analysis 
of effect modification by continuous age on the relationship between PM2.5 quartile 
exposure and mortality at 30 days yielded an LRT p-value of 0.2055. Adjusted odds ratios 
from the partially adjusted logistic regression model with interaction term included were 
as follows: quartile 1 = referent, quartile 2 = 1.01 (95% CI = 0.74-1.38), quartile 3 = 1.25 
(95% CI = 0.93-1.67), quartile 4 = 1.06 (95% CI = 0.78-1.45). Analysis of effect 
modification by categorical age on the relationship between PM2.5 quartiles and mortality 
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at 30 days yielded an LRT p-value of 0.0463. Adjusted odds ratios from the partially 
adjusted logistic regression model with interaction term included were as follows: <65 
years (Q1) = referent, <65 years (Q2) = 0.81 (95% CI = 0.46-1.43), <65 years (Q3) = 1.59 
(95% CI = 0.96-2.64), <65 years (Q4) = 0.95 (95% CI = 0.55-1.65), 65+ years (Q1) = 
referent, 65+ years (Q2) = 1.21 (95% CI = 0.90-1.63), 65+ years (Q3) = 1.08 (95% CI = 
0.80-1.46), 65+ years (Q4) = 1.24 (95% CI = 0.92-1.67). Analysis of effect modification 
by sex on the relationship between PM2.5 quartiles and mortality at 30 days yielded an LRT 
p-value of 0.5936. Adjusted odds ratios from the partially adjusted logistic regression 
model with interaction term included were as follows: male (Q1) = referent, male (Q2) = 
0.95 (95% CI = 0.66-1.37), male (Q3) = 1.17 (95% CI = 0.82-1.66), male (Q4) = 1.11 (95% 
CI = 0.78-1.58), female (Q1) = referent, female (Q2) = 1.31 (95% CI = 0.90-1.92), female 
(Q3) = 1.24 (95% CI = 0.85-1.82), female (Q4) = 1.25 (95% CI = 0.85-1.83). Analysis of 
effect modification by race on the relationship between PM2.5 quartiles and mortality at 30 
days yielded an LRT p-value of 0.2888. Adjusted odds ratios from the partially adjusted 
logistic regression model with interaction term included were as follows: white (Q1) = 
referent, white (Q2) = 1.12 (95% CI = 0.84-1.48), white (Q3) = 1.12 (95% CI = 0.85-1.47), 
white (Q4) = 1.11 (95% CI = 0.84-1.47), black (Q1) = referent, black (Q2) = 1.04 (95% CI 








Table 26: Effect modification by age (category) on the relationship between PM2.5 (quartile) exposure and 
mortality at 30 days – partially adjusted logistic regression modela with interaction term (N = 6145, events 
= 597) 
  Adjusted Odds Ratios by Category  
PM2.5 Quantile  
< 65 years (95% CI) 
n = 2712 
65+ years (95% CI) 
n = 3433 
LRT, p-value 
1 (≤ 7.07 μg/m3) referent 
n = 662 
x̅b = 5.51 
referent 
n = 868 
x̅b = 5.54 
0.0463 
 
2 (> 7.07 μg/m3 and ≤ 9.63 μg/m3) 0.81 (0.46-1.43) 
n = 678 
x̅b = 8.36 
1.21 (0.90-1.63) 
n = 858 
x̅b = 8.34 
3 (> 9.63 μg/m3 and ≤ 13.37 μg/m3) 1.59 (0.96-2.64) 
n = 681 
x̅b = 11.40 
1.08 (0.80-1.46) 
n = 865 
x̅b = 11.39 
4 (> 13.37 μg/m3) 0.95 (0.55-1.65) 
n = 691 
x̅b = 17.27 
1.24 (0.92-1.67) 
n = 842 
x̅b = 17.23 
a = Adjusting for age at enrollment (continuous), age at enrollment (categorical), sex, receival of pneumococcal vaccine, 
receival of seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy within the 
past 90 days, smoking history, and suspicion of aspiration 
b = Mean PM2.5 (continuous) for exposure / covariate category 
 
Table 27: Effect modification by sex on the relationship between PM2.5 
(quartile) exposure and mortality at 30 days – partially adjusted logistic regression 
modela with interaction term (N = 6145, events = 597) 
  Adjusted Odds Ratios by Category  
PM2.5 Quantile  
Male (95% CI) 
n = 2857 
Female (95% CI) 
n = 3288 
LRT, p-value 
1 (≤ 7.07 μg/m3) referent 
n = 703 
x̅b = 5.50 
referent 
n = 827 





2 (> 7.07 μg/m3 and ≤ 9.63 μg/m3) 0.95 (0.66-1.37) 
n = 728 
x̅b = 8.40 
1.31 (0.90-1.92) 
n = 808 
x̅b = 8.30 
3 (> 9.63 μg/m3 and ≤ 13.37 μg/m3) 1.17 (0.82-1.66) 
n = 709 
x̅b = 11.42 
1.24 (0.85-1.82) 
n = 837 
x̅b = 11.38 
4 (> 13.37 μg/m3) 1.11 (0.78-1.58) 
n = 717 
x̅b = 17.35 
1.25 (0.85-1.83) 
n = 816 
x̅b = 17.16 
a = Adjusting for age at enrollment (continuous), sex, receival of pneumococcal vaccine, receival of 
seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy 
within the past 90 days, smoking history, and suspicion of aspiration 






Table 28: Effect modification by race on the relationship between PM2.5 
(quartile) exposure and mortality at 30 days – partially adjusted logistic regression 
modela with interaction term (N = 6113, events = 596) 
  Adjusted Odds Ratios by Category  
PM2.5 Quantile  
White (95% CI) 
n = 4872 
Black (95% CI) 
n = 1241 
LRT, p-value 
1 (≤ 7.07 μg/m3) referent 
n = 1219 
x̅b = 5.55 
Referent 
n = 302 





2 (> 7.07 μg/m3 and ≤ 9.63 μg/m3) 1.12 (0.84-1.48) 
n = 1203 
x̅b = 8.36 
1.04 (0.48-2.26) 
n = 322 
x̅b = 8.30 
3 (> 9.63 μg/m3 and ≤ 13.37 μg/m3) 1.12 (0.85-1.47) 
n = 1225 
x̅b = 11.38 
1.95 (0.95-3.98) 
n = 315 
x̅b = 11.47 
4 (> 13.37 μg/m3) 1.11 (0.84-1.47) 
n = 1225 
x̅b = 17.29 
1.65 (0.79-3.44) 
n = 302 
x̅b = 17.10 
a = Adjusting for age at enrollment (continuous), sex, receival of pneumococcal vaccine, receival of 
seasonal influenza vaccine, race, PSI, direct transfer to ICU, receival of intravenous antibiotic therapy 
within the past 90 days, smoking history, and suspicion of aspiration 












The purpose of this study was to determine the impact of particulate matter 
exposure on the incidence of mortality assumed to be associated with community-acquired 
pneumonia. It is generally understood that PM is detrimental to humans in a number of 
ways, but the extent of this harm is still being studied, with new findings being reported 
each year. Though perhaps falling away from the spotlight in recent time due to the 
demands of the global SARS coronavirus 2 pandemic, the threat of this omnipresent 
pollutant remains present and substantive. PM exposure has placed a great burden upon 
human populations across the world, both in terms of morbidity and mortality, and its 
impact has been felt even more greatly among those populations lacking the resources to 
reduce such exposures. The oft invisible threat of airborne pollutants such as PM is as much 
a matter of health equity, of environmental justice, as it is of general health concern; it is 
only by fully understanding the scope and magnitude of this issue that we can begin to take 
meaningful steps to reverse it. 
The initial regression models examined in Aim One of this study seemed to indicate 
that little in the way of significant association existed between PM exposures and mortality 
within thirty days. The results in the literature are often to the contrary, generally 
suggesting that PM is associated with increased mortality to some degree (54, 69, 79-82, 
98). It is possible that the lack of significant findings in Aim One may have been partly 
due to residual confounding in analyzed relationships, present as a result of variable 
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categorization choices or by failure to include unnoted confounders. Attempts were made 
to reduce residual confounding by utilizing variables as they were defined in the dataset 
and without extensive categorical modification; for example, continuous age was utilized 
over categorized age in the bulk of modeling, as continuous age was the stronger variable 
and was also the variable presented in the dataset. Additionally, spatial averaging is a fairly 
simplistic interpolation technique, and the combination of the use of this method along 
with limited PM monitoring data may have resulted in the presence of error in the utilized 
exposure data. The Aim One results varied little between the two regression types used, as 
well as between the PM groups analyzed. It was only after examining the role of PM and 
mortality among select groups that the less-evident impact of exposure became more 
apparent.  
Analysis of PM10 Exposure 
 Based upon likelihood ratio test results, race was significantly indicated as an effect 
modifier in the relationship between PM10 exposure and mortality at thirty days. This effect 
was seen when examining exposure from both a continuous perspective and as quartiles. 
Black participants in the study had 19% higher odds of death at thirty days for every five-
unit increase of PM10 exposure that occurred on the day of their hospitalization. Those 
black participants that fell into the fourth quartile of PM10 exposure had 2.7-times higher 
odds of death within thirty days than those in the first quartile of exposure after adjusting 
for confounders and strong predictors. No such relationships between PM10 and mortality 
were detected among the white population of the study. Though not the same pollutant, 
increased PM2.5 exposure has been linked to elevated mortality risk among nonwhite and 
black participants among the 2000-2012 US Medicare population compared to white 
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participants, suggesting the harmful impact of PM exposure may be unequally experienced 
among racial groups in the US (79, 80).  
Overall, examination of race and PM10 exposure indicated a possible 
disproportionate and worryingly high association with mortality at thirty days among black 
participants in the highest exposure quartile. Geospatial mapping of participant racial 
distribution placed the vast majority of black participants within west and central 
Louisville; this could be of concern assuming this sample distribution is representative of 
the general population distribution, as localized PM sources within these areas could 
disproportionately impact a large section of the black population due to limited residential 
variation across space. The map itself was not included to protect the identities of study 
participants. To a limited extent, the findings revealed that black participants had slightly 
elevated means of PM10 exposure versus white participants (e.g., Q4 black participants: 
mean = 27.01 μg/m3; Q4 white participants: mean = 26.94 μg/m3). This idea was in line 
with existing literature, which has suggested that black individuals within the US have an 
average PM burden 1.5 times that of the overall population (87), though the magnitude of 
observed mean differences was not as extensive within this study. 
Additional examination of the black participant population revealed that those who 
fell within the highest exposure quartile had elevated relative risk of outcome occurrence 
versus those who fell within the lower exposure quartiles, but the association was only of 
borderline significance (relative risk = 1.51, 95% CI = 0.95-2.39). Though individual risks 
associated with each exposure quartile were below 10% and therefore relatively rare, it was 
possible the calculated relative risk was different from the observed adjusted odds ratio due 
to the inherent possibility that odds ratios can overestimate relative risk; also, the calculated 
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relative risk did not account for confounders and predictors.  It was also noted that black 
participants seemed to fall within the PSI classes IV and V less than white participants, 
possibly suggesting black participants ultimately had fewer risk factors for pneumonia 
mortality than white participants. If that were the case, however, why was it that significant 
or borderline significant elevations in odds or relative risk of outcome occurrence were 
only observed among black participants, and only among those with the highest levels of 
PM10 exposure? Ultimately, the outcome used in the study only examined all-cause 
mortality within thirty days, so it may be that elevated PM10 influenced thirty-day mortality 
due to non-pneumonia causes disproportionately among black participants, despite the 
likelihood of pneumonia mortality being generally lower for this sub-population. Other 
factors not examined in this study, such as socioeconomic status and proximity to roadways 
and other PM point-sources, may have also influenced the observed results, and will be 
included in future analyses (99-101). 
Both continuous and categorized age were also recognized as significant effect 
modifiers in the relationship between PM10 quartiles of exposure and mortality at thirty 
days based upon LRT results, though no significant measures of association were observed 
among the age/quartile relationships examined. Though not significant, the 65+ years old 
group consistently seemed to show increased odds of mortality in PM10 exposure quartiles 
two through three, as compared to the referent quartile (Q2: AOR = 1.28, 95% CI = 0.95-
1.72; Q3: AOR = 1.05, 95% CI = 0.77-1.43; Q4: AOR = 1.30, 95% CI = 0.96-1.76). Greater 
age being attributed to greater mortality associated with PM exposure has been observed 
in past literature, such as in the 2000-2012 US Medicare population previously mentioned, 
where individuals 85 years and older had significantly elevate relative risk associated with 
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each 10 μg/m3 increase in PM2.5 they were exposed to, versus those who were 69 years and 
younger (79). It should be noted that continuous age was also a significant confounder of 
the main relationship examined in the regression models (e.g. 2% increase in odds per one-
year increase in the partially adjusted continuous PM10 logistic model). 
Sex was not recognized to be an effect modifier as the previous two variables were, 
but still presented some significant findings. First, quantile exposure analysis revealed that 
female participants in the fourth exposure quartile had 46% higher odds of death within 
thirty days than those in the first exposure quartile. Such a relationship was not observed 
among male participants. Though not entirely clear, it is possible that female participants 
are more greatly impacted, or simply differently impacted, by environmental contaminants 
such as PM10 than male participants. This phenomenon has been observed in the literature, 
where females have been noted to have greater total and coarse particle deposition in the 
lungs than males (83). Additionally, females have been found to be at greater risk of death 
via respiratory illness induced by PM exposure (78).  Female marathon runners, but not 
their male counterparts, have been found to have significantly reduced performance as a 
result of increased PM10 exposure (84). The findings of our study, as well as those found 
in the literature, suggest the possibility that females experience PM exposure differently 
from males, and that elevated exposure may be a significantly greater source of harm for 
them. 
Sex was also noted to be a confounder in the regression models, though it seemed 
to only maintain statistical significance in the minimally adjusted models. In the minimally 
adjusted Aim One regression models, it was found that male participants had higher odds 
of death at thirty days than female participants (e.g., male participants had increased odds 
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of 41% in the minimally adjusted continuous PM10 logistic model). The outcome reversal 
among the two sexes that occurred at greater levels of PM10 exposure does lend credence 
to the possibility that female participants were more susceptible to the harmful effects of 
PM exposure at higher levels than male participants, despite males seemingly having 
higher thirty-day mortality in general. 
Receival status of both the pneumococcal and seasonal influenza vaccinations were 
variables recognized as confounders, and both presented significant findings of interest in 
the Aim One regression models. Pneumococcal vaccine receival status was consistently 
significant throughout the models and appeared to be associated with a substantial 
reduction in outcome likelihood (e.g., participants who had received the vaccine had 
reduced odds of 24% in the partially adjusted continuous PM10 logistic model). Seasonal 
influenza vaccine receival status was only significant in the minimally adjusted models but 
was associated with reduced outcome likelihood under these conditions (e.g., participants 
who had received the vaccine had reduced odds of 18% in the minimally adjusted 
continuous PM10 logistic model). Though the benefits of the seasonal influenza vaccine are 
questionable for the outcome of this particular study, the results do indicate that the 
pneumococcal vaccine can potentially improve survival likelihood in patients hospitalized 
for CAP. 
Not surprisingly, several variables linked to increased CAP risk or severity of 
disease in past literature were consistently found to be significant predictors of increased 
mortality at thirty days throughout the Aim One models (19, 32, 33, 37, 52); all values 
presented in this paragraph are from the partially adjusted continuous PM10 logistic model. 
Those participants who fell within the PSI classes IV and V had greater odds of mortality 
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within thirty days than those who were in class I, with AORs of 4.05 and 11.13, 
respectively. Those who were transferred to the ICU upon hospitalization had 65% greater 
odds of dying within thirty days than those who were not transferred to the ICU. Those 
who received intravenous antibiotic therapy within the past ninety days had 55% greater 
odds of dying within thirty days than those who did not receive IV antibiotics. Those who 
were considered to be at-risk for aspiration had 62% greater odds of dying within thirty 
days than those not at risk for aspiration. 
Surprisingly, smoking status was not significantly associated with increased 
likelihood of outcome. Most current smokers were comparatively younger in age, with 
68.6% being under the age of 65 years. The majority of past smokers, 73.3%, were 65 years 
or older. Though not significant, it was strange to observe that participants among the 
previously mentioned categories were at reduced likelihood of mortality at thirty days 
compared to non-smokers. It is unclear why such relationships were observed. One 
possibility is that the current smokers who participated in the study may be relatively low-
risk smokers. This could mean that those who were at greater risk of the outcome due to 
smoking may have already died, while those left may be less prone to complications due 
to smoking. In addition to being younger, 55% of the current smokers within the study fell 
within the first three classes of the PSI, suggesting the majority of the included current 
smoker population was at lower risk of mortality resulting from pneumonia, often due to 
having less risk factors (e.g., comorbidities) that would increase pneumonia severity. 
Assuming it is the case that the included current smokers were lower risk smokers, this 
appears to be an example of volunteer bias, meaning that those current smokers who 
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volunteered to take part in the study did not necessarily represent the current smokers 
within the general population.  
Comments Concerning Analysis of PM2.5 Exposure 
 Largely, results of models containing variations of PM2.5 as the exposure closely 
mimicked those of corresponding PM10 models. In Aim One, AORs and AHRs for all 
covariates from models containing variations of PM2.5 as the exposure were very similar to 
those reported in corresponding models containing variations of PM10 as the exposure and 
were significant in all the same ways.  Diverging from this similarity were the PM2.5 
exposure models of Aim Three, which did not reflect the same effect modification results 
and significant findings as those reported for the PM10 exposure models. It was found that 
categorized age was an effect modifier of the main relationship of study, but no other 
significant associations were otherwise revealed. No significant relationships were 
observed among the Aim Three analyses, despite the fact that past studies have found 
increased levels of PM2.5 to be associated with elevated relative risk of mortality for older 
individuals, nonwhites, and female and male individuals (79, 80). PM10 and PM2.5, though 
both forms of particulate matter, are distinct particles, and form from different processes 
and likely have differing chemical compositions (60, 61); it is possible that the differences 
in observed results between the two forms of particulate matter in Aim Three analyses are 
partially due to biological differences in how participants reacted to the two types of 
exposure particulates. 
Comments Concerning the Use of Kriging 
 The models resulting from the attempted use of kriging in this study were ultimately 
of little use from a prediction standpoint. Inability to run kriging models for small amounts 
95 
 
of data and the observation of questionable patterns based on sparse data points were 
significant indicators that more advanced geospatial / geostatistical interpolation methods 
require robust sources of data to adequately function. A sufficient sample size is required 
to yield useful results for Kriging. The results clearly illustrated the importance of 
sufficient sample size when conducting kriging. No concrete lower quantity limit of data 
point sources exists for this method, but the number is likely dependent on the size of the 
area being examined. In this case, the study area was quite large, and the number of point 
sources comparatively small, numbering four or fewer for the entire 398 square mile area. 
Future kriging efforts pertaining to PM concentrations would benefit greatly from either 
the use of alternative, more spatially abundant data sources or by the taking of new, 
localized PM measurements for a variety of points across the study area. 
Strengths 
 There are several strengths evident within the study. First, the HAPPI dataset itself 
is robust and effectively mimics the established demographic profile of the study region in 
many ways, with clear exception being given to the average age of study participants versus 
that of the general population. This is to be expected, given the HAPPI population is 
entirely composed of CAP-hospitalized individuals, who tend to be inherently older in age. 
Second, the HAPPI dataset accurately characterizes the burden of CAP among hospitalized 
individuals within the study timeframe, given the relative accessibility of the study and the 
high level of recruitment involved. Third, the HAPPI sample is relatively large in size, 
ensuring adequate power for most of the analyses that were carried out. Fourth, though 
relatively simplistic in methodology, the use of spatial averaging allowed for estimation of 
participant PM exposure where more advanced methods could not adequately function. 
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Fifth, the HAPPI dataset supplied temporal data for the cohort, which allowed for survival 
analysis to be conducted. The temporal data also provided a clear timeline for exposure 
and outcome occurrence, ultimately proving that the former preceded the latter. Sixth, 
participant information was based upon electronic medical records, which are largely 
accurate and up-to-date, and often reduce the chance for issues such as recall bias that result 
from the use of alternate data sources (e.g., self-completed questionnaires). Finally, access 
to limited death certificate information ensured that those who were reported as 
manifesting the outcome did truly experience the outcome. 
Limitations  
As in any study, some limitations were present. Perhaps the most substantial 
limitation was the fact that address-specific PM concentration measurements were not 
available for study participants, and that such values had to be interpolated from data 
provided by the small number of monitoring stations located within the study area. Though 
having to interpolate such values was not ideal, it did provide experience in utilizing 
geostatistical methods. A second limitation was that the sparsity of monitoring stations, 
and therefore PM point values, severely limited the ability to use more complicated 
geostatistical interpolation methods – kriging, in this case. A third limitation was that cause 
of death information was largely unavailable for study participants, necessitating the use 
of a proxy outcome in place of mortality directly attributed to CAP. A fourth limitation 
was that the current study only examined PM exposure at the time of hospitalization. This 
allowed for the examination of the short-term impact of PM on thirty-day mortality, but 
not the long-term impact. Examining the impact of PM concentrations at alternative points 
in time, such as at one month prior to hospitalization, may have given a better 
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understanding of the exposure/outcome relationship in the long-term. Data for analysis of 
long-term impacts are available, meaning the capacity exists to examine these relationships 
going forward. A final limitation was that the current study did not account for 
socioeconomic status, proximity to PM point-sources, or seasonality; these variables were 
not directly included in the datasets utilized. 
Future Research  
            The key associations of interest largely yielded results that were not statistically 
significant; however, the findings that were significant provided useful insights into factors 
that may influence the outcome and into groups that may be at greater risk due to exposure. 
Being able to address the data limitations present in the current study would serve as a boon 
to further research endeavors on the subject. Use of a more abundant exposure data source 
that better characterizes the entirety of the study area would be ideal (e.g., having a larger 
number of sampling sites distributed across the county, use of remote sensing data to 
characterize PM levels (102) by census block group). Having access to cause of death 
information would also be ideal, as it would allow for a more thorough examination of the 
impact of PM on CAP-specific mortality. It is clear from the existing literature, and from 
the study to a certain extent, that PM exposure is potentially harmful, and further work is 
needed to determine the exact nature of the relationship between PM exposure and CAP-
associated mortality. In addition to fixing data limitation issues, such work would include 
examination of long-term PM exposure impact on the occurrence of the outcome, as well 





 Those female and black participants who fell within the highest levels of PM10 
exposure within the established exposure quartiles had significantly increased odds of 
mortality at thirty days, as compared to those who fell within the referent lowest exposure 
quartile. Additionally, numerous other factors, including pneumococcal vaccine receival 
status, elevated PSI class, transfer to the ICU at the time of hospitalization, receival of 
intravenous antibiotic therapy within the past ninety days, and being at risk for aspiration, 
were significantly associated with the outcome, and may influence or help predict outcome 
likelihood. Kriging is a robust spatial interpolation method, and though it was not found to 
be a functional option within this particular study, may be useful in future work where 
exposure point data are more plentiful. All-together, the results indicate that elevated 
particulate matter exposure may increase the odds of mortality among certain groups within 
a population of adults hospitalized for community-acquired pneumonia, suggesting that 
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• Proficient in Microsoft Word, Excel, PowerPoint, and in navigation of the 
Internet.  
• Proficient knowledge of SAS and STATA statistical programs. 
• OSHA and Laboratory Safety certified. 
• Working knowledge of GIS for public health purposes.  
• Proficient in use of REDCap survey tool. 
Writing 
• Extensive knowledge of academic writing and reading.  
• Excellent grammar skills. 
Presentation 
• Strong public-speaking skills and familiarity with speaking in front of groups. 
• Comfortable working in field / community environments. 




University of Louisville, Community Engagement Academy 2018-2019 
• Learned methods and skills to best address the need for increased community 
engaged research in modern academia 
• Discussed research ethics as they apply to community engagement 
• Developed a community engaged research project in connection with Green Heart 
Louisville utilizing learned methods and skills 
 
